Amgen (AMGN) 10-K16 Feb 222021 FY Annual reportFinancial data

Company Profile

Cover page

Cover page - USD ($)	12 Months Ended
Cover page - USD ($)	Dec. 31, 2021	Feb. 11, 2022	Jun. 30, 2021
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-37702
Entity Registrant Name	Amgen Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 137,531,019,585
Entity Common Stock, Shares Outstanding		557,029,370
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s Proxy Statement with respect to the 2022 Annual Meeting of Stockholders to be held May 17, 2022, are incorporated by reference into Part III of this annual report.
Entity Central Index Key	0000318154
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Common Stock \| The NASDAQ Global Select Market
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
2.00% Senior Notes Due 2026 \| New York Stock Exchange
Entity Information [Line Items]
Title of 12(b) Security	2.00% Senior Notes due 2026
Trading Symbol	AMGN26
Security Exchange Name	NASDAQ

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2021
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Los Angeles, California

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 25,979	$ 25,424	$ 23,362
Operating expenses:
Cost of sales	6,454	6,159	4,356
Research and development	4,819	4,207	4,116
Acquired in-process research and development	1,505	0	0
Selling, general and administrative	5,368	5,730	5,150
Other	194	189	66
Total operating expenses	18,340	16,285	13,688
Operating income	7,639	9,139	9,674
Interest expense, net	(1,197)	(1,262)	(1,289)
Other income, net	259	256	753
Income before income taxes	6,701	8,133	9,138
Provision for income taxes	808	869	1,296
Net income	$ 5,893	$ 7,264	$ 7,842
Earnings per share:
Basic (in usd per share)	$ 10.34	$ 12.40	$ 12.96
Diluted (in usd per share)	$ 10.28	$ 12.31	$ 12.88
Shares used in the calculation of earnings per share:
Basic (in shares)	570	586	605
Diluted (in shares)	573	590	609
Product sales
Revenues:
Total revenues	$ 24,297	$ 24,240	$ 22,204
Other revenues
Revenues:
Total revenues	$ 1,682	$ 1,184	$ 1,158

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 5,893	$ 7,264	$ 7,842
Other comprehensive income (loss), net of reclassification adjustments and taxes:
(Losses) gains on foreign currency translation	(135)	9	(48)
Gains (losses) on cash flow hedges	324	(438)	(66)
(Losses) gains on available-for-sale securities	(1)	(21)	360
Other	1	(7)	(5)
Other comprehensive income (loss), net of taxes	189	(457)	241
Comprehensive income	$ 6,082	$ 6,807	$ 8,083

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 7,989	$ 6,266
Marketable securities	48	4,381
Trade receivables, net	4,895	4,525
Inventories	4,086	3,893
Other current assets	2,367	2,079
Total current assets	19,385	21,144
Property, plant and equipment, net	5,184	4,889
Intangible assets, net	15,182	16,587
Goodwill	14,890	14,689
Other noncurrent assets	6,524	5,639
Total assets	61,165	62,948
Current liabilities:
Accounts payable	1,366	1,421
Accrued liabilities	10,731	10,141
Current portion of long-term debt	87	91
Total current liabilities	12,184	11,653
Long-term debt	33,222	32,895
Long-term tax liabilities	6,594	6,968
Other noncurrent liabilities	2,465	2,023
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—558.3 shares in 2021 and 578.3 shares in 2020	32,096	31,802
Accumulated deficit	(24,600)	(21,408)
Accumulated other comprehensive loss	(796)	(985)
Total stockholders’ equity	6,700	9,409
Total liabilities and stockholders’ equity	$ 61,165	$ 62,948

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	558.3	578.3

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Cumulative effect of changes in accounting principles, net of taxes	Number of shares of common stock	Common stock and additional paid-in capital	Accumulated deficit	Accumulated deficitCumulative effect of changes in accounting principles, net of taxes	Accumulated other comprehensive (loss) income
Beginning Balance, Shares at Dec. 31, 2018			629.6
Beginning Balance at Dec. 31, 2018	$ 12,500			$ 31,246	$ (17,977)		$ (769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,842				7,842
Other comprehensive income (loss), net of tax	241						241
Dividends declared on common stock	(3,555)				(3,555)
Issuance of common stock in connection with the Company’s equity award programs, Shares			2
Issuance of common stock in connection with the Company’s equity award programs	97			97
Stock-based compensation expense	323			323
Tax impact related to employee stock-based compensation expense	(135)			(135)
Repurchases of common stock, Shares			(40.2)
Repurchases of common stock	(7,640)				(7,640)
Ending Balance, Shares at Dec. 31, 2019			591.4
Ending Balance at Dec. 31, 2019	9,673	$ (2)		31,531	(21,330)	$ (2)	(528)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,264				7,264
Other comprehensive income (loss), net of tax	(457)						(457)
Dividends declared on common stock	(3,843)				(3,843)
Issuance of common stock in connection with the Company’s equity award programs, Shares			2.1
Issuance of common stock in connection with the Company’s equity award programs	91			91
Stock-based compensation expense	349			349
Tax impact related to employee stock-based compensation expense	(169)			(169)
Repurchases of common stock, Shares			(15.2)
Repurchases of common stock	$ (3,497)				(3,497)
Ending Balance, Shares at Dec. 31, 2020	578.3		578.3
Ending Balance at Dec. 31, 2020	$ 9,409			31,802	(21,408)		(985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	5,893				5,893
Other comprehensive income (loss), net of tax	189						189
Dividends declared on common stock	(4,098)				(4,098)
Issuance of common stock in connection with the Company’s equity award programs, Shares			1.7
Issuance of common stock in connection with the Company’s equity award programs	82			82
Stock-based compensation expense	361			361
Tax impact related to employee stock-based compensation expense	(149)			(149)
Repurchases of common stock, Shares			(21.7)
Repurchases of common stock	$ (4,987)				(4,987)
Ending Balance, Shares at Dec. 31, 2021	558.3		558.3
Ending Balance at Dec. 31, 2021	$ 6,700			$ 32,096	$ (24,600)		$ (796)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	Dec. 03, 2021	Oct. 31, 2021	Jul. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Jul. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Oct. 31, 2019	Jul. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 1.94	$ 1.76	$ 1.76	$ 1.76	$ 1.76	$ 1.60	$ 1.60	$ 1.60	$ 1.60	$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 7.22	$ 6.56	$ 5.95

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income	$ 5,893	$ 7,264	$ 7,842
Depreciation, amortization and other	3,398	3,601	2,206
Stock-based compensation expense	341	330	308
Deferred income taxes	(453)	(287)	(289)
Acquired in-process research and development	1,505	0	0
Other items, net	(229)	(195)	(186)
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	(429)	(427)	(504)
Inventories	(165)	(215)	(66)
Other assets	(237)	129	10
Accounts payable	(69)	45	164
Accrued income taxes, net	(854)	(249)	(585)
Long-term tax liabilities	204	(482)	(146)
Other liabilities	356	983	396
Net cash provided by operating activities	9,261	10,497	9,150
Cash flows from investing activities:
Purchases of marketable securities	(8,900)	(8,477)	(9,394)
Proceeds from sales of marketable securities	4,403	2,597	8,842
Proceeds from maturities of marketable securities	8,831	4,381	20,548
Purchases of property, plant and equipment	(880)	(608)	(618)
Cash paid for acquisitions, net of cash acquired	(2,529)	0	(13,617)
Purchases of equity method investments	(157)	(3,219)	(24)
Other	(35)	(75)	(28)
Net cash provided by (used in) investing activities	733	(5,401)	5,709
Cash flows from financing activities:
Net proceeds from issuance of debt	4,945	8,914	0
Repayment of debt	(4,150)	(6,450)	(4,514)
Repurchases of common stock	(4,975)	(3,486)	(7,702)
Dividends paid	(4,013)	(3,755)	(3,509)
Other	(78)	(90)	(42)
Net cash used in financing activities	(8,271)	(4,867)	(15,767)
Increase (decrease) in cash and cash equivalents	1,723	229	(908)
Cash and cash equivalents at beginning of year	6,266	6,037	6,945
Cash and cash equivalents at end of year	$ 7,989	$ 6,266	$ 6,037

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
Summary of significant accounting policies	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&A expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur. Research and development costs R&D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations. Selling, general and administrative costs SG&A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations. Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate. Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation. Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. Acquisitions We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement. Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase. Interest-bearing securities We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement. Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories. Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment. Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets’ estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets. Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Foreign currency translation The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars by using average exchange rates. Equity investments Marketable and nonmarketable equity securities Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income. Equity method investments Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income. Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income. Recent accounting pronouncements In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2021
Business Combinations [Abstract]
Business combinations	Acquisitions Teneobio, Inc. On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and BiTE ® platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 994 Contingent consideration 309 Total consideration $ 1,303 Cash and cash equivalents $ 100 IPR&D 1,054 Finite-lived intangible asset – R&D technology rights 94 Finite-lived intangible assets – licensing rights 41 Goodwill 251 Other assets, net 16 Deferred tax liability (253) Total assets acquired, net $ 1,303 The consideration for this transaction were (i) an upfront cash payment of $994 million, which included a working-capital adjustment and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair value of the contingent consideration obligations aggregated $309 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pre-tax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2021. The estimated fair values of acquired IPR&D assets totaled $1.1 billion, of which $784 million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of mCRPC, and the balance relates to four separate preclinical oncology programs. The R&D technology rights of $94 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies and will be amortized over ten years using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. A deferred tax liability of $253 million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $251 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired. Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date. Five Prime Therapeutics, Inc. On April 16, 2021, Amgen acquired the outstanding stock of Five Prime for total consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. The operations of Five Prime have been included in our consolidated financial statements commencing after the acquisition date. We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&D program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The acquired IPR&D expense was not tax deductible. Otezla On November 21, 2019, we acquired worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene. Otezla is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla. The operations of Otezla have been included in our consolidated financial statements commencing on the acquisition date. The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 13,400 Transaction costs 40 Accumulated cost (consideration transferred) $ 13,440 Intangible assets: Developed-product-technology rights $ 13,007 Marketing-related rights 195 Inventory 367 Deferred tax liability, net (24) Deferred credit (96) Other liabilities, net (9) Total assets acquired, net $ 13,440 Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired. The developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method. The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce is being amortized over a period of 5 years by using the straight-line method. The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer’s effort are applied. Inventory fair value adjustments is being amortized as inventory turns over, which we estimate to approximate 2.5 years. Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million. The tax effects of the acquisition are based on Amgen’s estimated blended statutory tax rate of 20%. Nuevolution AB On July 15, 2019, we acquired all of the outstanding stock of Nuevolution, a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution’s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date. We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million. The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.

Revenues

Revenues	12 Months Ended
Revenues	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe. Revenues were as follows (in millions): Year ended December 31, 2021 Year ended December 31, 2020 Year ended December 31, 2019 U.S. ROW Total U.S. ROW Total U.S. ROW Total Enbrel $ 4,352 $ 113 $ 4,465 $ 4,855 $ 141 $ 4,996 $ 5,050 $ 176 $ 5,226 Prolia 2,150 1,098 3,248 1,830 933 2,763 1,772 900 2,672 Otezla (1) 1,804 445 2,249 1,790 405 2,195 139 39 178 XGEVA 1,434 584 2,018 1,405 494 1,899 1,457 478 1,935 Neulasta 1,514 220 1,734 2,001 292 2,293 2,814 407 3,221 Aranesp 537 943 1,480 629 939 1,568 758 971 1,729 Repatha 557 560 1,117 459 428 887 376 285 661 KYPROLIS 736 372 1,108 710 355 1,065 654 390 1,044 Nplate 566 461 1,027 485 365 850 480 315 795 Other products 3,636 2,215 5,851 3,821 1,903 5,724 3,031 1,712 4,743 Total product sales (2) 17,286 7,011 24,297 17,985 6,255 24,240 16,531 5,673 22,204 Other revenues 908 774 1,682 511 673 1,184 693 465 1,158 Total revenues $ 18,194 $ 7,785 $ 25,979 $ 18,496 $ 6,928 $ 25,424 $ 17,224 $ 6,138 $ 23,362 ____________ (1) Otezla was acquired on November 21, 2019. (2) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019. In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2021, 2020 and 2019. For the year ended December 31, 2021, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2021 2020 2019 McKesson Corporation: Gross product sales $ 15,187 $ 13,779 $ 11,795 % of total gross revenues 33 % 32 % 31 % AmerisourceBergen Corporation: Gross product sales $ 14,783 $ 14,743 $ 12,301 % of total gross revenues 32 % 34 % 33 % Cardinal Health, Inc.: Gross product sales $ 7,681 $ 7,332 $ 6,538 % of total gross revenues 17 % 17 % 17 %

Stock-based compensation

Stock-based compensation	12 Months Ended
Stock-based compensation	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2021, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 19 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose. The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2021 2020 2019 RSUs $ 183 $ 178 $ 168 Performance units 121 118 105 Stock options 37 34 35 Total stock-based compensation expense, pretax 341 330 308 Tax benefit from stock-based compensation expense (74) (72) (67) Total stock-based compensation expense, net of tax $ 267 $ 258 $ 241 Restricted stock units and stock options Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee’s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs. Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient. Restricted stock units The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2021, 2020 and 2019, were $233.10, $235.63 and $182.12, respectively. The following table summarizes information regarding our RSUs: Year ended December 31, 2021 Units Weighted-average Balance nonvested as of December 31, 2020 3.0 $ 198.11 Granted 1.3 $ 233.10 Vested (0.9) $ 177.27 Forfeited (0.4) $ 213.32 Balance nonvested as of December 31, 2021 3.0 $ 217.95 The total grant date fair values of RSUs that vested during the years ended December 31, 2021, 2020 and 2019, were $166 million, $161 million and $160 million, respectively. Stock options The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black–Scholes option valuation model to estimate the grant date fair value of stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2021 2020 2019 Closing price of our common stock on grant date $ 237.17 $ 236.36 $ 177.31 Expected volatility (average of implied and historical volatility) 25.6 % 28.1 % 23.5 % Expected life (in years) 5.7 5.8 5.8 Risk-free interest rate 1.0 % 0.4 % 2.4 % Expected dividend yield 2.9 % 3.0 % 3.1 % Fair value of stock options granted $ 40.43 $ 42.34 $ 30.47 The following table summarizes information regarding our stock options: Year ended December 31, 2021 Options Weighted- Weighted- Aggregate Balance unexercised as of December 31, 2020 4.7 $ 179.90 Granted 1.3 $ 237.17 Exercised (0.5) $ 137.95 Expired/forfeited (0.4) $ 208.56 Balance unexercised as of December 31, 2021 5.1 $ 197.27 7.3 $ 168 Vested or expected to vest as of December 31, 2021 4.9 $ 195.64 7.2 $ 167 Exercisable as of December 31, 2021 2.0 $ 165.46 5.6 $ 120 The total intrinsic values of options exercised during the years ended December 31, 2021, 2020 and 2019, were $56 million, $98 million and $68 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2021, 2020 and 2019, were $12 million, $21 million and $15 million, respectively. As of December 31, 2021, $346 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years. Performance units Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2021, 2020 and 2019, which are accounted for as equity awards, are based on (i) Amgen’s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen’s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned. We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2021 2020 2019 Closing price of our common stock on grant date $ 239.64 $ 236.36 $ 177.31 Volatility 29.3 % 27.5 % 22.1 % Risk-free interest rate 0.3 % 0.2 % 2.3 % Fair value of units granted $ 254.68 $ 249.07 $ 188.40 The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units. As of December 31, 2021 and 2020, 1.6 million and 1.8 million performance units were outstanding, with weighted-average grant date fair values per unit of $229.39 and $207.52 per unit, respectively. During the year ended December 31, 2021, 0.6 million performance units with a weighted-average grant date fair value per unit of $254.68 were granted, and 0.2 million performance units with a weighted-average grant date fair value per unit of $226.32 were forfeited. The total fair values of performance units paid during the years ended December 31, 2021, 2020 and 2019, were $149 million, $230 million and $176 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.

Defined contribution plan

Defined contribution plan	12 Months Ended
Defined contribution plan	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined contribution plan	Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $279 million, $231 million and $220 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Income taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income before income taxes included the following (in millions): Years ended December 31, 2021 2020 2019 Domestic $ 1,850 $ 4,087 $ 4,371 Foreign 4,851 4,046 4,767 Total income before income taxes $ 6,701 $ 8,133 $ 9,138 The provision for income taxes included the following (in millions): Years ended December 31, 2021 2020 2019 Current provision: Federal $ 865 $ 921 $ 1,284 State 18 34 39 Foreign 359 277 277 Total current provision 1,242 1,232 1,600 Deferred benefit: Federal (308) (321) (276) State (9) 9 (22) Foreign (117) (51) (6) Total deferred benefit (434) (363) (304) Total provision for income taxes $ 808 $ 869 $ 1,296 Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2021 2020 Deferred income tax assets: NOL and credit carryforwards $ 1,065 $ 794 Accrued expenses 600 561 Expenses capitalized for tax 244 144 Stock-based compensation 96 92 Other 326 301 Total deferred income tax assets 2,331 1,892 Valuation allowance (663) (571) Net deferred income tax assets 1,668 1,321 Deferred income tax liabilities: Acquired intangible assets (824) (903) Debt (275) (282) Fixed assets (129) (148) Other (221) (189) Total deferred income tax liabilities (1,449) (1,522) Total deferred income taxes, net $ 219 $ (201) Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. The valuation allowance increased in 2021, primarily driven by the Company’s expectation that some state R&D credits will not be utilized and certain foreign and acquired net operating losses will expire unused. As of December 31, 2021, we had $75 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2040. We had $798 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $709 million of those state tax credit carryforwards. As of December 31, 2021, we had $606 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. For the federal NOL carryforwards for which no valuation allowance has been provided, $426 million have no expiration; the remainder begin to expire between 2022 and 2037. We had $391 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $330 million of those state NOL carryforwards. We had $2.0 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $561 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $800 million has no expiry; and the remainder will expire between 2022 and 2031. The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2021 2020 2019 Beginning balance $ 3,352 $ 3,287 $ 3,061 Additions based on tax positions related to the current year 171 165 215 Additions based on tax positions related to prior years 35 3 22 Reductions for tax positions of prior years (4) (35) (11) Settlements (8) (68) — Ending balance $ 3,546 $ 3,352 $ 3,287 Substantially all of the UTBs as of December 31, 2021, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly. Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2021, 2020 and 2019, we recognized $98 million, $116 million and $198 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2021, was primarily due to lower interest rates during 2021 and settlement of a prior year audit. As of December 31, 2021 and 2020, accrued interest and penalties associated with UTBs were $881 million and $783 million, respectively. The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2021 2020 2019 Federal statutory tax rate 21.0 % 21.0 % 21.0 % Foreign earnings (7.8) % (4.7) % (4.5) % Foreign-derived intangible income (1.0) % (0.7) % (0.7) % Credits, Puerto Rico excise tax (3.4) % (2.9) % (2.6) % Interest on uncertain tax positions 1.1 % 1.1 % 1.6 % Credits, primarily federal R&D (2.1) % (1.4) % (1.0) % Acquisition IPR&D 4.9 % — % — % Audit settlements — % (1.0) % — % Other, net (0.6) % (0.7) % 0.4 % Effective tax rate 12.1 % 10.7 % 14.2 % The effective tax rates for the years ended December 31, 2021, 2020 and 2019, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company’s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes in 2021, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. Income taxes paid during the years ended December 31, 2021, 2020 and 2019, were $1.9 billion, $1.4 billion and $1.9 billion, respectively. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities (including the IRS) are becoming more aggressive and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021, which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS’s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013–15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions. Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.

Earnings per share

Earnings per share	12 Months Ended
Earnings per share	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2021 2020 2019 Income (Numerator): Net income for basic and diluted EPS $ 5,893 $ 7,264 $ 7,842 Shares (Denominator): Weighted-average shares for basic EPS 570 586 605 Effect of dilutive securities 3 4 4 Weighted-average shares for diluted EPS 573 590 609 Basic EPS $ 10.34 $ 12.40 $ 12.96 Diluted EPS $ 10.28 $ 12.31 $ 12.88 For each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Collaborations

Collaborations	12 Months Ended
Collaborations	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity. From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below. BeiGene, Ltd. On January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene. During the years ended December 31, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $220 million and $225 million, respectively, and were recorded as an offset to R&D expense in the Consolidated Statements of Income. During the year ended December 31, 2021, product sales from Amgen to BeiGene under the collaboration were $72 million and were recorded in Product sales in the Consolidated Statements of Income. During the year ended December 31, 2021, profit and loss share expenses related to the initial product-specific commercialization period were $64 million and were recorded primarily in SG&A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $21 million and $22 million as of December 31, 2021 and 2020, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $61 million and $99 million as of December 31, 2021 and 2020, respectively, which are included in Other current assets in the Consolidated Balance Sheets. Novartis Pharma AG We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Note 19, Contingencies and commitments. Arrangement through December 31, 2021 In the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal, recognized product sales of Aimovig in the United States, shared U.S. commercialization costs with Novartis and paid Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&D expenses. In addition, Novartis was required to make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States. Arrangement after January 1, 2022 Pursuant to the amendment effective January 1, 2022, Novartis retains the ex-U.S. Novartis Rights and will continue to pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide. In the United States, Novartis will no longer collaborate with Amgen or share Aimovig commercialization costs and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide . Amgen manufactures and supplies Aimovig worldwide. During the years ended December 31, 2021, 2020 and 2019, net costs recovered from Novartis for migraine products were $160 million, $192 million and $187 million, respectively, and were recorded primarily in SG&A expense in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due to Novartis for Aimovig were $116 million, $139 million and $115 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due from Novartis for Aimovig were not material. Kyowa Kirin Co., Ltd. On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize an anti-OX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases. Under the terms of the agreement, we will lead the global development, manufacture and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia. We made an upfront payment of $400 million to KKC that was recognized in R&D expense in the third quarter of 2021. Amgen and KKC will share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs due to KKC were not material during the year ended December 31, 2021. Other In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of December 31, 2021 Amortized Gross Gross Fair U.S. Treasury notes $ 47 $ — $ — $ 47 U.S. Treasury bills 1,400 — — 1,400 Money market mutual funds 5,856 — — 5,856 Other short-term interest-bearing securities 1 — — 1 Total available-for-sale investments $ 7,304 $ — $ — $ 7,304 Types of securities as of December 31, 2020 Amortized Gross Gross Fair U.S. Treasury notes $ 129 $ 1 $ — $ 130 U.S. Treasury bills 4,948 — — 4,948 Money market mutual funds 4,765 — — 4,765 Other short-term interest-bearing securities 2 — — 2 Total available-for-sale investments $ 9,844 $ 1 $ — $ 9,845 The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2021 2020 Cash and cash equivalents $ 7,256 $ 5,464 Marketable securities 48 4,381 Total available-for-sale investments $ 7,304 $ 9,845 Cash and cash equivalents in the above table excludes bank account cash of $733 million and $802 million as of December 31, 2021 and 2020, respectively. The fair values of available-for-sale investments by contractual maturity were as follows (in millions): December 31, Contractual maturities 2021 2020 Maturing in one year or less $ 7,304 $ 9,795 Maturing after one year through three years — 50 Total available-for-sale investments $ 7,304 $ 9,845 For the years ended December 31, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. For the year ended December 31, 2019, realized gains on interest-bearing securities were $92 million and realized losses were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. Equity securities We held investments in equity securities with readily determinable fair values of $611 million and $477 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2021, 2020 and 2019, net unrealized gains on publicly traded securities were $161 million, $174 million and $112 million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2021, 2020 and 2019, were not material. We held investments of $262 million and $203 million in equity securities without readily determinable fair values as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent ass ets in the Consolidated Balance Sheets. For the year ended December 31, 2021, gains due to upward adjustments on these securities were $152 million, and gains realized on the dispositions of these securities were $41 million; for the years ended December 31, 2020 and 2019, gains due to upward adjustments and gains realized upon dispositions of these securities were not material. For the years ended December 31, 2021, 2020 and 2019, downward adjustments to the carrying values of these securities were not material. Adjustments were based on observable price transactions. Equity Method Investments BeiGene, Ltd. On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8 billion, of which $2.6 billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets. Our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as sets of BeiGene by approximately $2.4 billion. The equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years. During the years ended December 31, 2021 and 2020, the carrying value of the investment was reduced by our share of BeiGene’s net losses of $265 million and $229 million, respectively, and amortization of the basis difference of $172 million and $109 million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $50 million and $569 million, respectively, as a result of our purchase of additional shares of BeiGene. In addition, during the years ended December 31, 2021 and 2020, the carrying value increased by $265 million and $34 million, respectively, from the impact of other BeiGene ownership transactions. As of December 31, 2021 and 2020, our ownership interest in BeiGene was approximately 18.4% and 20.5%, respectively. As of December 31, 2021 and 2020, the carrying value of our investment in BeiGene was $2.8 billion and $2.9 billion, respectively. As of December 31, 2021 and 2020, the fair value of our investment in BeiGene was $5.1 billion and $4.9 billion, respectively. We believe that as of December 31, 2021, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations. Neumora Therapeutics, Inc. On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257 million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $100 million cash payment and $157 million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of December 31, 2021, our ownership interest in Neumora remained at approximately 25.9%, and the fair value of our investment was $220 million. Accordingly, during the fourth quarter of 2021, we recognized a loss of $37 million for the reduction in the fair value in Other income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement. Limited partnerships We held limited partnership investments of $573 million and $496 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2021, unfunded additional commitments to be made for these investments during the next several years were $185 million. For the years ended December 31, 2021, 2020 and 2019, net gains recognized from our limited partnership investments were $143 million, $241 million and $27 million, respectively.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): December 31, 2021 2020 Raw materials $ 647 $ 486 Work in process 2,367 2,437 Finished goods 1,072 970 Total inventories $ 4,086 $ 3,893

Property, plant and equipment

Property, plant and equipment	12 Months Ended
Property, plant and equipment	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2021 2020 Land — $ 279 $ 259 Buildings and improvements 10-40 4,028 3,857 Manufacturing equipment 8-12 3,080 2,865 Laboratory equipment 8-12 1,193 1,257 Fixed equipment 12 2,402 2,406 Capitalized software 3-5 1,151 1,216 Other 5-10 862 1,091 Construction in progress — 987 915 Property, plant and equipment, gross 13,982 13,866 Less accumulated depreciation and amortization (8,798) (8,977) Property, plant and equipment, net $ 5,184 $ 4,889 During the years ended December 31, 2021, 2020 and 2019, we recognized depreciation and amortization expense associated with our property, plant and equipment of $644 million, $640 million and $635 million, respectively. Geographic information Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions): December 31, 2021 2020 United States $ 2,801 $ 2,473 Puerto Rico 1,311 1,331 ROW 1,072 1,085 Total property, plant and equipment, net $ 5,184 $ 4,889

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
Goodwill and intangible assets	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in millions): December 31, 2021 2020 Beginning balance $ 14,689 $ 14,703 Addition from acquisitions 251 — Currency translation adjustments (50) (14) Ending balance $ 14,890 $ 14,689 Other intangible assets Other intangible assets consisted of the following (in millions): December 31, 2021 2020 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 25,561 $ (12,769) $ 12,792 $ 25,591 $ (10,564) $ 15,027 Licensing rights 3,807 (2,973) 834 3,743 (2,791) 952 Marketing-related rights 1,354 (1,112) 242 1,367 (1,041) 326 R&D technology rights 1,377 (1,133) 244 1,317 (1,065) 252 Total finite-lived intangible assets 32,099 (17,987) 14,112 32,018 (15,461) 16,557 Indefinite-lived intangible assets: IPR&D 1,070 — 1,070 30 — 30 Total other intangible assets $ 33,169 $ (17,987) $ 15,182 $ 32,048 $ (15,461) $ 16,587 Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&D projects may vary from their estimated fair values. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the year ended December 31, 2021, we acquired certain finite-lived and indefinite-lived intangible assets as a result of the Teneobio acquisition, including IPR&D of $1.1 billion, R&D technology rights of $94 million and licensing rights of $41 million. See Note 2, Acquisitions.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2021
Leases [Abstract]
Leases	Leases We lease certain facilities and equipment related primarily to administrative, R&D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets. Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&D and administrative space. The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): December 31, Consolidated Balance Sheets locations 2021 2020 Assets: Other noncurrent assets $ 566 $ 408 Liabilities: Accrued liabilities $ 145 $ 153 Other noncurrent liabilities 525 306 Total lease liabilities $ 670 $ 459 The components of net lease costs were as follows (in millions): Years ended December 31, Lease costs 2021 2020 2019 Operating (1) $ 237 $ 223 $ 204 Sublease income (38) (34) (33) Total net lease costs $ 199 $ 189 $ 171 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019. Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): Maturity dates Amounts 2022 $ 148 2023 148 2024 75 2025 49 2026 44 Thereafter 289 Total lease payments (1) 753 Less imputed interest (83) Present value of lease liabilities $ 670 ____________ (1) Includes future rental commitments for abandoned leases of $138 million. We expect to receive total future rental income of $108 million related to noncancelable subleases for abandoned facilities. The weighted-average remaining lease terms and weighted-average discount rates were as follows: December 31, 2021 2020 Weighted-average remaining lease term (in years) 8.3 3.7 Weighted-average discount rate 2.5 % 3.1 % Cash and noncash information related to our leases was as follows (in millions): Years ended December 31, 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 190 $ 177 $ 148 ROU assets obtained in exchange for lease obligations: Operating leases $ 340 $ 101 $ 163 As of December 31, 2021, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $35 million. These leases will commence in 2022 with lease terms from 4 to 6 years.

Other current assets and accrue

Other current assets and accrued liabilities	12 Months Ended
Other current assets and accrued liabilities	Dec. 31, 2021
Payables and Accruals [Abstract]
Other current assets and accrued liabilities	Other current assets and accrued liabilities Other current assets consisted of the following (in millions): December 31, 2021 2020 Prepaid expenses $ 1,223 $ 1,156 Corporate partner receivables 780 583 Tax receivables 164 216 Other 200 124 Total other current assets $ 2,367 $ 2,079 Accrued liabilities consisted of the following (in millions): December 31, 2021 2020 Sales deductions $ 5,174 $ 4,801 Dividends payable 1,083 1,018 Employee compensation and benefits 1,081 1,098 Income taxes payable 701 828 Sales returns reserve 542 474 Other 2,150 1,922 Total accrued liabilities $ 10,731 $ 10,141

Financing arrangements

Financing arrangements	12 Months Ended
Financing arrangements	Dec. 31, 2021
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): December 31, 2021 2020 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) — 1,527 2.70% notes due 2022 (2.70% 2022 Notes) — 500 2.65% notes due 2022 (2.65% 2022 Notes) — 1,500 3.625% notes due 2022 (3.625% 2022 Notes) — 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 767 791 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 500 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 853 916 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 643 649 2.20% notes due 2027 (2.20% 2027 Notes) 1,750 1,750 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 1.65% notes due in 2028 (1.65% 2028 Notes) 1,250 — 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 947 957 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 1,250 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 1,250 2.00% notes due 2032 (2.00% 2032 Notes) 1,250 — 6.375% notes due 2037 (6.375% 2037 Notes) 478 478 6.90% notes due 2038 (6.90% 2038 Notes) 254 254 6.40% notes due 2039 (6.40% 2039 Notes) 333 333 3.15% notes due 2040 (3.15% 2040 Notes) 2,000 2,000 5.75% notes due 2040 (5.75% 2040 Notes) 373 373 2.80% notes due 2041 (2.80% 2041 Notes) 1,150 — 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 729 729 5.65% notes due 2042 (5.65% 2042 Notes) 415 415 5.375% notes due 2043 (5.375% 2043 Notes) 185 185 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 2,250 2,250 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 3.00% notes due 2052 (3.00% 2052 Notes) 1,350 — 2.77% notes due 2053 (2.77% 2053 Notes) 940 940 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (1,213) (1,188) Fair value adjustments 284 566 Other 15 5 Total carrying value of debt 33,309 32,986 Less current portion (87) (91) Total long-term debt $ 33,222 $ 32,895 There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively. Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes—except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097—may be redeemed at any time at our option—in whole or in part—at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity. Debt issuances During the years ended December 31, 2021 and 2020, we issued debt securities in the following offerings: • In 2021, we issued $5.0 billion of debt consisting of $1.25 billion of the 1.65% 2028 Notes, $1.25 billion of the 2.00% 2032 Notes, $1.15 billion of the 2.80% 2041 Notes and $1.35 billion of the 3.00% 2052 Notes. • In 2020, we issued $9.0 billion of debt consisting of $500 million of the 1.90% 2025 Notes, $1.75 billion of the 2.20% 2027 Notes, $1.25 billion of the 2.45% 2030 Notes, $1.25 billion of the 2.30% 2031 Notes, $2.0 billion of the 3.15% 2040 Notes and $2.25 billion of the 3.375% 2050 Notes. We did not issue any debt or debt securities during the year ended December 31, 2019. Debt repayments/redemptions We made debt repayments/redemptions during the years ended December 31, 2021, 2020 and 2019, as follows: • In 2021, we redeemed $4.2 billion of debt, including the €1.25 billion aggregate principal amount ($1.4 billion upon settlement of the related cross-currency swap) of the 1.25% 2022 euro Notes, the $500 million aggregate principal amount of the 2.70% 2022 Notes, the $1.5 billion aggregate principal amount of the 2.65% 2022 Notes and the $750 million aggregate principal amount of the 3.625% 2022 Notes. In connection with the redemption of these notes, we paid a total of $24 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income. • In 2020, we repaid/redeemed $6.5 billion of debt, including the repayment at maturity of the $300 million aggregate principal amount of the 4.50% 2020 Notes, the $750 million aggregate principal amount of the 2.125% 2020 Notes, the $300 million Floating Rate Notes due 2020 and the $700 million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900 million aggregate principal amount of the 3.45% 2020 Notes, the $1.0 billion aggregate principal balance of the 4.10% 2021 Notes, the $750 million aggregate principal balance of the 1.85% 2021 Notes and the $1.75 billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income. • In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the €675 million aggregate principal amount ($864 million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019. Interest rate swaps To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges. During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes and an aggregate notional amount of $500 million with respect to the 2.30% 2031 Notes. In connection with the redemption of the 3.625% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $750 million were terminated. In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65 billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments. The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2021 December 31, 2020 Notes Notional amounts Effective interest rates Notional amounts Effective interest rates 3.625% 2022 Notes $ — N/A $ 750 LIBOR + 2.7% 3.625% 2024 Notes 1,400 LIBOR + 3.2% 1,400 LIBOR + 3.2% 3.125% 2025 Notes 1,000 LIBOR + 1.8% 1,000 LIBOR + 1.8% 2.60% 2026 Notes 1,250 LIBOR + 1.8% 1,250 LIBOR + 1.8% 2.45% 2030 Notes 1,000 LIBOR + 1.0% — N/A 2.30% 2031 Notes 500 LIBOR + 0.8% — N/A 4.663% 2051 Notes 1,500 LIBOR +4.1% 1,500 LIBOR + 4.1% Total notional amounts $ 6,650 $ 5,900 N/A = not applicable Debt exchange In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940 million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer). The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions): Principal amount exchanged 6.375% 2037 Notes $ 74 6.90% 2038 Notes $ 37 6.40% 2039 Notes $ 133 5.75% 2040 Notes $ 39 5.15% 2041 Notes $ 245 5.65% 2042 Notes $ 72 5.375% 2043 Notes $ 76 The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration). The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income. Cross-currency swaps To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments. In connection with the redemption of the 1.25% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of €1.25 billion were terminated. Shelf registration statement and other facilities As of December 31, 2021, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2021 and 2020, we had no amounts outstanding under our commercial paper program. In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2021 and 2020, no amounts were outstanding under this facility. In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023. Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2021. Contractual maturities of debt obligations The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions): Maturity dates Amounts 2022 $ — 2023 1,517 2024 1,400 2025 1,500 2026 2,746 Thereafter 27,075 Total $ 34,238 Interest costs Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2021, 2020 and 2019, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2021, 2020 and 2019, were $1.2 billion, $1.2 billion and $1.3 billion, respectively.

Stockholders' equity

Stockholders' equity	12 Months Ended
Stockholders' equity	Dec. 31, 2021
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): Years ended December 31, 2021 2020 2019 Shares Dollars Shares Dollars Shares* Dollars First quarter 3.7 $ 865 4.3 $ 933 15.9 $ 3,031 Second quarter 6.5 1,592 2.6 591 13.1 2,349 Third quarter 4.6 1,069 3.0 752 6.2 1,170 Fourth quarter 6.9 1,461 5.3 1,221 5.1 1,090 Total stock repurchases 21.7 $ 4,987 15.2 $ 3,497 40.2 $ 7,640 * Total shares do not add due to rounding. In March 2021, October 2021 and December 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $3.4 billion, $4.5 billion and $5.0 billion, respectively. As of December 31, 2021, $10.9 billion remained available under our stock repurchase program. Dividends Our Board of Directors declared quarterly dividends per share of $1.76, $1.60 and $1.45, which were paid in each of the four quarters of 2021, 2020 and 2019, respectively. Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 3, 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. Accumulated other comprehensive loss The components of AOCI were as follows (in millions): Foreign Cash flow Available-for-sale Other AOCI Balance as of December 31, 2018 $ (670) $ 241 $ (338) $ (2) $ (769) Foreign currency translation adjustments (48) — — — (48) Unrealized gains — 127 424 — 551 Reclassification adjustments to income — (211) (56) — (267) Other losses — — — (5) (5) Income taxes — 18 (8) — 10 Balance as of December 31, 2019 (718) 175 22 (7) (528) Foreign currency translation adjustments 9 — — — 9 Unrealized (losses) gains — (61) 6 — (55) Reclassification adjustments to income — (501) (33) — (534) Other losses — — — (7) (7) Income taxes — 124 6 — 130 Balance as of December 31, 2020 (709) (263) 1 (14) (985) Foreign currency translation adjustments (135) — — — (135) Unrealized gains (losses) — 159 (1) — 158 Reclassification adjustments to income — 253 — — 253 Other gains — — — 1 1 Income taxes — (88) — — (88) Balance as of December 31, 2021 $ (844) $ 61 $ — $ (13) $ (796) With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $33 million expense and a $55 million expense in 2021, a $14 million benefit and a $110 million benefit in 2020 and a $28 million expense and a $46 million benefit in 2019, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020 and a $22 million expense and a $14 million benefit in 2019, respectively. Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2021 2020 2019 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract (losses) gains $ (8) $ 178 $ 101 Product sales Cross-currency swap contract (losses) gains (245) 323 110 Other income, net (253) 501 211 Income before income taxes 55 (110) (46) Provision for income taxes $ (198) $ 391 $ 165 Net income Available-for-sale securities: Net realized gains $ — $ 33 $ 56 Other income, net — (7) (14) Provision for income taxes $ — $ 26 $ 42 Net income Other In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2021 and 2020, no shares of preferred stock were issued or outstanding.

Fair value measurement

Fair value measurement	12 Months Ended
Fair value measurement	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2021, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury notes $ 47 $ — $ — $ 47 U.S. Treasury bills 1,400 — — 1,400 Money market mutual funds 5,856 — — 5,856 Other short-term interest-bearing securities — 1 — 1 Equity securities 611 — 220 831 Derivatives: Foreign currency contracts — 183 — 183 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 16 — 16 Total assets $ 7,914 $ 266 $ 220 $ 8,400 Liabilities: Derivatives: Foreign currency contracts $ — $ 39 $ — $ 39 Cross-currency swap contracts — 339 — 339 Interest rate swap contracts — 156 — 156 Contingent consideration obligations — — 342 342 Total liabilities $ — $ 534 $ 342 $ 876 Fair value measurement as of December 31, 2020, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury notes $ 130 $ — $ — $ 130 U.S. Treasury bills 4,948 — — 4,948 Money market mutual funds 4,765 — — 4,765 Other short-term interest-bearing securities — 2 — 2 Equity securities 477 — — 477 Derivatives: Foreign currency contracts — 28 — 28 Cross-currency swap contracts — 255 — 255 Interest rate swap contracts — 66 — 66 Total assets $ 10,320 $ 351 $ — $ 10,671 Liabilities: Derivatives: Foreign currency contracts $ — $ 237 $ — $ 237 Cross-currency swap contracts — 318 — 318 Interest rate swap contracts — 15 — 15 Contingent consideration obligations — — 33 33 Total liabilities $ — $ 570 $ 33 $ 603 Interest-bearing and equity securities The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair values of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available information for similar companies that have actively traded equity securities. Derivatives All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments. Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments. Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments. Contingent consideration obligations As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): Years ended December 31, 2021 2020 2019 Beginning balance $ 33 $ 61 $ 72 Additions 309 — — Payments (7) (6) — Net changes in valuations 7 (22) (11) Ending balance $ 342 $ 33 $ 61 As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $1.6 billion upon achieving separate development and regulatory milestones with regard to various R&D programs. See Note 2, Acquisitions. As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Borrowings We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2021 and 2020, the aggregate fair values of our borrowings were $37.9 billion and $39.4 billion, respectively, and the carrying values were $33.3 billion and $33.0 billion, respectively. Investment in BeiGene We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2021 and 2020, the fair values were $5.1 billion and $4.9 billion, and the carrying values were $2.8 billion and $2.9 billion, respectively. During the years ended December 31, 2021 and 2020, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.

Derivative instruments

Derivative instruments	12 Months Ended
Derivative instruments	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods. As of December 31, 2021, 2020 and 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.7 billion, $5.1 billion and $5.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 % During the year ended December 31, 2021, our 1.25% euro Notes were redeemed, and the related cross-currency swaps were settled, resulting in an immaterial loss. During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts to hedge variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2021, and amounts expected to be recognized during the subsequent 12 months are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2021 2020 2019 Foreign currency contracts $ 373 $ (251) $ 148 Cross-currency swap contracts (214) 190 (21) Total unrealized gains (losses) $ 159 $ (61) $ 127 Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2021 and 2020, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion and $5.9 billion, respectively, that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps. During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.5 billion. Interest rate swaps with an aggregate notional value of $750 million were terminated in connection with the redemption of certain of our notes. The resulting gain on these terminations was immaterial. During the year ended December 31, 2020, interest rate swaps with an aggregate notional value of $3.7 billion were terminated in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $40 million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $5.2 billion aggregate notional amount of interest rate swaps, which resulted in receipt of $576 million from the counterparties and which was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount is being recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt. The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2021 2020 2021 2020 Current portion of long-term debt $ 85 $ 89 $ 85 $ 89 Long-term debt $ 6,729 $ 6,258 $ 199 $ 477 ____________ (1) Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. (2) Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2021 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,297 $ 259 $ (1,197) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ (8) $ — $ — Cross-currency swap contracts $ — $ (245) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 281 Derivatives designated as hedging instruments $ — $ — $ (192) Year ended December 31, 2020 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,240 $ 256 $ (1,262) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 178 $ — $ — Cross-currency swap contracts $ — $ 323 $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 315 Derivatives designated as hedging instruments $ — $ — $ (204) Year ended December 31, 2019 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,204 $ 753 $ (1,289) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 101 $ — $ — Cross-currency swap contracts $ — $ 110 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (349) Derivatives designated as hedging instruments $ — $ — $ 352 __________ (1) Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2021, we expected to reclassify $19 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2021, 2020 and 2019, the total notional amounts of these foreign currency forward contracts were $680 million, $1.0 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2021, 2020 and 2019. The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2021 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other noncurrent assets $ 183 Accrued liabilities/ Other noncurrent liabilities $ 39 Cross-currency swap contracts Other current assets/ Other noncurrent assets 66 Accrued liabilities/ Other noncurrent liabilities 339 Interest rate swap contracts Other current assets/ Other noncurrent assets 16 Accrued liabilities/ Other noncurrent liabilities 156 Total derivatives designated as hedging instruments 265 534 Total derivatives $ 265 $ 534 Derivative assets Derivative liabilities December 31, 2020 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other noncurrent assets $ 28 Accrued liabilities/ Other noncurrent liabilities $ 237 Cross-currency swap contracts Other current assets/ Other noncurrent assets 255 Accrued liabilities/ Other noncurrent liabilities 318 Interest rate swap contracts Other current assets/ Other noncurrent assets 66 Accrued liabilities/ Other noncurrent liabilities 15 Total derivatives designated as hedging instruments 349 570 Total derivatives $ 349 $ 570 Our derivative contracts that were in liability positions as of December 31, 2021, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our, or the surviving entity’s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.

Contingencies and commitments

Contingencies and commitments	12 Months Ended
Contingencies and commitments	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: ANDA Patent Litigation Otezla ANDA Patent Litigation Amgen Inc. v. Sandoz Inc., et al. Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the ’940 Patent), 7,208,516 (the ’516 Patent), 7,427,638 (the ’638 Patent), 7,659,302 (the ’302 Patent), 7,893,101 (the ’101 Patent), 8,455,536 (the ’536 Patent), 8,802,717 (the ’717 Patent), 9,018,243 (the ’243 Patent) and 9,872,854 (the ’854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant’s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, Celgene Corp. v. Sandoz Inc., et al. Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant’s ANDA effective no earlier than the expiration of the applicable patents. In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the ’330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the ’541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the ’940, ’302, ’536, ’243 and ’330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the ’283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, Celgene Corp. v. Sandoz Inc., et al . Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark’s apremilast product during the term of the ’940, ’638, ’302, ’101, ’536, ’243, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. Following Amgen’s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff. On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem’s apremilast product during the term of the ’940, ’638, ’302, ’101, ’536, ’243, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero’s apremilast product during the term of the ’940, ’516, ’638, ’302, ’101, ’536, ’717, ’243, ’330, ’854 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure’s apremilast product during the term of the ’638, ’101, ’854 and ’541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the ’717, ’516 and ’854 Patents, leaving the ’940, ’302, ’536, ’243, ’330, ’638, ’101 and ’541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind’s apremilast product during the term of the ’940, ’302, ’536, ’243, ’330, ’638, ’101 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods’ apremilast product during the term of the ’638 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal’s apremilast product during the term of the ’101, ’940, ’638, ’302, ’536, ’243, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa’s apremilast product during the term of the ’638, ’101 and ’854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis’ apremilast product during the term of the ’940, ’516, ’638, ’302, ’536, ’717, ’330, ’854 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston’s apremilast product during the term of the ’638 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo’s apremilast product during the term of the ’940, ’516, ’638, ’302, ’101, ’536, ’717, ’243, ’330, ’854 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla’s apremilast product during the term of the ’940, ’638, ’302, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent’s apremilast product during the term of the ’101, ’638, ’854 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem’s apremilast product during the term of the ’940, ’638, ’302, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN’s apremilast product during the term of the ’940, ’638, ’302, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience’s apremilast product during the term of the ’243, ’940, ’638, ’302, ’101, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL’s apremilast product during the term of the ’638, ’101, ’536 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the ’638 Patent, claim 6 of the ’536 Patent and claims 2 and 27 of the ’283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the ’101 Patent and claims 2, 19 and 21 of the ’541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus’s ANDA must be after expiration of the three infringed patents (the ’638, ’536 and ’283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus’s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the ’638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court. On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the ’638 Patent, claim 6 of the ’536 Patent and claims 1 and 15 of the ’101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the ’541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz’s ANDA must be after expiration of the three infringed patents (the ’638, ’536 and ’101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz’s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the ‘638 and ‘101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court. ENBREL Patent Litigation Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd. On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis’ submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen’s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the ’522 Patent), 7,915,225, 8,119,605 and 8,722,631. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis’ etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court’s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis. On November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche’s ’522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties’ submission. Repatha Patent Litigation Amgen Inc., et al. v. Sanofi, et al. In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the ’165 Patent); 8,859,741 (the ’741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron’s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen’s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron’s infringement of Amgen’s patents is willful. In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen’s patents, including claims 2, 7, 9, 15, 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron’s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen’s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court’s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents). In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron’s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court’s conclusion that the judgment affirming the validity of Amgen’s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen’s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron’s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen’s claim of willful infringement. On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent. The jury also found that claims 7 and 15 of the ’165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron’s request for a new trial and their request to reverse the jury verdict that the ’165 Patent and the ’741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court’s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent as lacking an enabling disclosure of the invention. On January 11, 2022, the U.S. Supreme Court requested that Sanofi and Regeneron file a response to Amgen’s petition, which is due March 14, 2022. Patent Disputes in the International Region We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen’s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen’s patent. In November 2018, the EPO confirmed the validity of Amgen’s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA’s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA’s October 29, 2020 ruling. On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.’s appeals making final the Japanese High Court’s decisions that PRALUENT infringes Amgen’s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen’s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron’s invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. NEUPOGEN (filgrastim)/Neulasta Patent Litigation Amgen Inc., et al. v. Hospira Inc. et al. On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Hospira Inc. and Pfizer Inc. (collectively, Pfizer). This lawsuit stems from Pfizer’s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen’s Neulasta. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the ’707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the ’707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the ’707 Patent. In June 2020, the FDA approved Pfizer’s NYVEPRIA, a biosimilar to Amgen’s Neulasta. On April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction. Currently pending before the Delaware District Court is Pfizer’s motion for summary judgment of noninfringement, which has been fully briefed. No date has been set for argument on the motion. Patent Trial and Appeal Board (PTAB) Challenge Apotex PTAB Challenge In February 2017, the PTAB of the USPTO granted Apotex’s petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the ’138 Patent), challenging claims of the ’138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the ’138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. On May 20, 2019, the PTAB issued a decision denying Apotex’s request for rehearing on the PTAB’s finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen’s ’138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court’s decision in Arthrex Inc. v. Smith & Nephew, Inc ., 941 F.3d 1320 (Fed. Cir. 2019). On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the ’138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the ’138 Patent, for proceedings consistent with its decision in Arthrex Inc. v. Smith & Nephew, Inc. , requesting that such remanded cases be held pending the U.S. Supreme Court’s disposition of the petition for writ of certiorari in United States v. Arthrex, Inc. , No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government’s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court. On June 21, 2021, the U.S. Supreme Court decided United States v. Arthrex, Inc. On June 28, 2021, the U.S. Supreme Court granted the government’s pending certiorari petition and vacated and remanded the Federal Circuit Court’s judgment for further consideration under Arthrex. On September 2, 2021, the Federal Circuit Court issued a remand to permit Amgen to request rehearing of the PTAB’s final written decision holding that all claims of the ’138 Patent as unpatentable. On October 4, 2021, Amgen filed a request for the USPTO Director for a rehearing and review of the Final Written Decision pursuant to Arthrex . On November 22, 2021, the Director denied this request. On December 6, 2021, Amgen filed the Notice of Director review with the patent office. Pfizer PTAB Challenge On February 10, 2021, Pfizer filed a petition to institute IPR proceeding at the USPTO of U.S. Patent No. 8,273,707 (the ’707 Patent), challenging claims of the ’707 Patent as unpatentable. Amgen’s preliminary response was filed on May 18, 2021. On August 17, 2021, the PTAB of the USPTO granted Pfizer’s petition to institute IPR of the ’707 Patent. On August 23, 2021, the PTAB issued the schedule for the proceeding, including oral argument (if requested) on May 18, 2022. On November 17, 2021, Amgen filed its Patent Owner’s Response. Breach of Contract Action Novartis Pharma AG v. Amgen Inc. On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis seeking a declaratory judgment that Novartis materially breached two collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig due to Novartis’ affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig and entrant in the CGRP-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis’ complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns, and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis’ first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Am

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II AMGEN INC. VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2021, 2020 and 2019 (In millions) Allowance for doubtful accounts Balance Additions Other Deductions Balance Year ended December 31, 2021 $ 32 $ — $ — $ (6) $ 26 Year ended December 31, 2020 $ 26 $ 8 $ — $ (2) $ 32 Year ended December 31, 2019 $ 48 $ — $ — $ (22) $ 26

Summary of significant accoun_2

Summary of significant accounting policies - (Policies)	12 Months Ended
Summary of significant accounting policies - (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Revenues and Arrangements with multiple performance obligations	Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&A expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.
Research and development costs	Research and development costs R&D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.
Selling, general and administrative costs	Selling, general and administrative costs SG&A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.
Leases	Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.
Stock-based compensation	Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.
Income taxes	Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.
Acquisitions	Acquisitions We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.
Cash equivalents	Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.
Interest-bearing securities	Interest-bearing securities We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.
Derivatives	Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.
Goodwill and other intangible assets	Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets’ estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.
Contingencies	Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Foreign currency translation	Foreign currency translation The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars by using average exchange rates.
Equity investments, policy	Equity investments Marketable and nonmarketable equity securities Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.
Equity method investments	Equity method investments Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income. Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.
Recent accounting pronouncements	Recent accounting pronouncements In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.

Acquisitions - (Tables)

Acquisitions - (Tables)	12 Months Ended
Acquisitions - (Tables)	Dec. 31, 2021
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 994 Contingent consideration 309 Total consideration $ 1,303 Cash and cash equivalents $ 100 IPR&D 1,054 Finite-lived intangible asset – R&D technology rights 94 Finite-lived intangible assets – licensing rights 41 Goodwill 251 Other assets, net 16 Deferred tax liability (253) Total assets acquired, net $ 1,303 The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 13,400 Transaction costs 40 Accumulated cost (consideration transferred) $ 13,440 Intangible assets: Developed-product-technology rights $ 13,007 Marketing-related rights 195 Inventory 367 Deferred tax liability, net (24) Deferred credit (96) Other liabilities, net (9) Total assets acquired, net $ 13,440

Revenues (Tables)

Revenues (Tables)	12 Months Ended
Revenues (Tables)	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue by product and by geographic area	Revenues were as follows (in millions): Year ended December 31, 2021 Year ended December 31, 2020 Year ended December 31, 2019 U.S. ROW Total U.S. ROW Total U.S. ROW Total Enbrel $ 4,352 $ 113 $ 4,465 $ 4,855 $ 141 $ 4,996 $ 5,050 $ 176 $ 5,226 Prolia 2,150 1,098 3,248 1,830 933 2,763 1,772 900 2,672 Otezla (1) 1,804 445 2,249 1,790 405 2,195 139 39 178 XGEVA 1,434 584 2,018 1,405 494 1,899 1,457 478 1,935 Neulasta 1,514 220 1,734 2,001 292 2,293 2,814 407 3,221 Aranesp 537 943 1,480 629 939 1,568 758 971 1,729 Repatha 557 560 1,117 459 428 887 376 285 661 KYPROLIS 736 372 1,108 710 355 1,065 654 390 1,044 Nplate 566 461 1,027 485 365 850 480 315 795 Other products 3,636 2,215 5,851 3,821 1,903 5,724 3,031 1,712 4,743 Total product sales (2) 17,286 7,011 24,297 17,985 6,255 24,240 16,531 5,673 22,204 Other revenues 908 774 1,682 511 673 1,184 693 465 1,158 Total revenues $ 18,194 $ 7,785 $ 25,979 $ 18,496 $ 6,928 $ 25,424 $ 17,224 $ 6,138 $ 23,362 ____________ (1) Otezla was acquired on November 21, 2019.
Revenues earned from major customers	Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2021 2020 2019 McKesson Corporation: Gross product sales $ 15,187 $ 13,779 $ 11,795 % of total gross revenues 33 % 32 % 31 % AmerisourceBergen Corporation: Gross product sales $ 14,783 $ 14,743 $ 12,301 % of total gross revenues 32 % 34 % 33 % Cardinal Health, Inc.: Gross product sales $ 7,681 $ 7,332 $ 6,538 % of total gross revenues 17 % 17 % 17 %

Stock-based compensation (Table

Stock-based compensation (Tables)	12 Months Ended
Stock-based compensation (Tables)	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Components of stock-based compensation expense recognized in the Consolidated Statements of Income	The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2021 2020 2019 RSUs $ 183 $ 178 $ 168 Performance units 121 118 105 Stock options 37 34 35 Total stock-based compensation expense, pretax 341 330 308 Tax benefit from stock-based compensation expense (74) (72) (67) Total stock-based compensation expense, net of tax $ 267 $ 258 $ 241
Summary of RSUs	The following table summarizes information regarding our RSUs: Year ended December 31, 2021 Units Weighted-average Balance nonvested as of December 31, 2020 3.0 $ 198.11 Granted 1.3 $ 233.10 Vested (0.9) $ 177.27 Forfeited (0.4) $ 213.32 Balance nonvested as of December 31, 2021 3.0 $ 217.95
Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options	The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2021 2020 2019 Closing price of our common stock on grant date $ 237.17 $ 236.36 $ 177.31 Expected volatility (average of implied and historical volatility) 25.6 % 28.1 % 23.5 % Expected life (in years) 5.7 5.8 5.8 Risk-free interest rate 1.0 % 0.4 % 2.4 % Expected dividend yield 2.9 % 3.0 % 3.1 % Fair value of stock options granted $ 40.43 $ 42.34 $ 30.47
Summary of stock options	The following table summarizes information regarding our stock options: Year ended December 31, 2021 Options Weighted- Weighted- Aggregate Balance unexercised as of December 31, 2020 4.7 $ 179.90 Granted 1.3 $ 237.17 Exercised (0.5) $ 137.95 Expired/forfeited (0.4) $ 208.56 Balance unexercised as of December 31, 2021 5.1 $ 197.27 7.3 $ 168 Vested or expected to vest as of December 31, 2021 4.9 $ 195.64 7.2 $ 167 Exercisable as of December 31, 2021 2.0 $ 165.46 5.6 $ 120
Weighted average assumptions used and the resulting weighted average grant date fair value of performance units	The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2021 2020 2019 Closing price of our common stock on grant date $ 239.64 $ 236.36 $ 177.31 Volatility 29.3 % 27.5 % 22.1 % Risk-free interest rate 0.3 % 0.2 % 2.3 % Fair value of units granted $ 254.68 $ 249.07 $ 188.40

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of income before income tax, domestic and foreign	Income before income taxes included the following (in millions): Years ended December 31, 2021 2020 2019 Domestic $ 1,850 $ 4,087 $ 4,371 Foreign 4,851 4,046 4,767 Total income before income taxes $ 6,701 $ 8,133 $ 9,138
Provision for income taxes	The provision for income taxes included the following (in millions): Years ended December 31, 2021 2020 2019 Current provision: Federal $ 865 $ 921 $ 1,284 State 18 34 39 Foreign 359 277 277 Total current provision 1,242 1,232 1,600 Deferred benefit: Federal (308) (321) (276) State (9) 9 (22) Foreign (117) (51) (6) Total deferred benefit (434) (363) (304) Total provision for income taxes $ 808 $ 869 $ 1,296
Significant components of deferred tax assets and liabilities	Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2021 2020 Deferred income tax assets: NOL and credit carryforwards $ 1,065 $ 794 Accrued expenses 600 561 Expenses capitalized for tax 244 144 Stock-based compensation 96 92 Other 326 301 Total deferred income tax assets 2,331 1,892 Valuation allowance (663) (571) Net deferred income tax assets 1,668 1,321 Deferred income tax liabilities: Acquired intangible assets (824) (903) Debt (275) (282) Fixed assets (129) (148) Other (221) (189) Total deferred income tax liabilities (1,449) (1,522) Total deferred income taxes, net $ 219 $ (201)
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)	The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2021 2020 2019 Beginning balance $ 3,352 $ 3,287 $ 3,061 Additions based on tax positions related to the current year 171 165 215 Additions based on tax positions related to prior years 35 3 22 Reductions for tax positions of prior years (4) (35) (11) Settlements (8) (68) — Ending balance $ 3,546 $ 3,352 $ 3,287
Reconciliation between the federal statutory tax rate and effective tax rate	The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2021 2020 2019 Federal statutory tax rate 21.0 % 21.0 % 21.0 % Foreign earnings (7.8) % (4.7) % (4.5) % Foreign-derived intangible income (1.0) % (0.7) % (0.7) % Credits, Puerto Rico excise tax (3.4) % (2.9) % (2.6) % Interest on uncertain tax positions 1.1 % 1.1 % 1.6 % Credits, primarily federal R&D (2.1) % (1.4) % (1.0) % Acquisition IPR&D 4.9 % — % — % Audit settlements — % (1.0) % — % Other, net (0.6) % (0.7) % 0.4 % Effective tax rate 12.1 % 10.7 % 14.2 %

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
Earnings per share (Tables)	Dec. 31, 2021
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2021 2020 2019 Income (Numerator): Net income for basic and diluted EPS $ 5,893 $ 7,264 $ 7,842 Shares (Denominator): Weighted-average shares for basic EPS 570 586 605 Effect of dilutive securities 3 4 4 Weighted-average shares for diluted EPS 573 590 609 Basic EPS $ 10.34 $ 12.40 $ 12.96 Diluted EPS $ 10.28 $ 12.31 $ 12.88

Investments - (Tables)

Investments - (Tables)	12 Months Ended
Investments - (Tables)	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of December 31, 2021 Amortized Gross Gross Fair U.S. Treasury notes $ 47 $ — $ — $ 47 U.S. Treasury bills 1,400 — — 1,400 Money market mutual funds 5,856 — — 5,856 Other short-term interest-bearing securities 1 — — 1 Total available-for-sale investments $ 7,304 $ — $ — $ 7,304 Types of securities as of December 31, 2020 Amortized Gross Gross Fair U.S. Treasury notes $ 129 $ 1 $ — $ 130 U.S. Treasury bills 4,948 — — 4,948 Money market mutual funds 4,765 — — 4,765 Other short-term interest-bearing securities 2 — — 2 Total available-for-sale investments $ 9,844 $ 1 $ — $ 9,845
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2021 2020 Cash and cash equivalents $ 7,256 $ 5,464 Marketable securities 48 4,381 Total available-for-sale investments $ 7,304 $ 9,845
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of available-for-sale investments by contractual maturity were as follows (in millions): December 31, Contractual maturities 2021 2020 Maturing in one year or less $ 7,304 $ 9,795 Maturing after one year through three years — 50 Total available-for-sale investments $ 7,304 $ 9,845

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions): December 31, 2021 2020 Raw materials $ 647 $ 486 Work in process 2,367 2,437 Finished goods 1,072 970 Total inventories $ 4,086 $ 3,893

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
Property, plant and equipment (Tables)	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Components of property, plant and equipment	Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2021 2020 Land — $ 279 $ 259 Buildings and improvements 10-40 4,028 3,857 Manufacturing equipment 8-12 3,080 2,865 Laboratory equipment 8-12 1,193 1,257 Fixed equipment 12 2,402 2,406 Capitalized software 3-5 1,151 1,216 Other 5-10 862 1,091 Construction in progress — 987 915 Property, plant and equipment, gross 13,982 13,866 Less accumulated depreciation and amortization (8,798) (8,977) Property, plant and equipment, net $ 5,184 $ 4,889
Property, plant and equipment by geographic information	Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions): December 31, 2021 2020 United States $ 2,801 $ 2,473 Puerto Rico 1,311 1,331 ROW 1,072 1,085 Total property, plant and equipment, net $ 5,184 $ 4,889

Goodwill and other intangible a

Goodwill and other intangible assets - (Tables)	12 Months Ended
Goodwill and other intangible assets - (Tables)	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The changes in the carrying amounts of goodwill were as follows (in millions): December 31, 2021 2020 Beginning balance $ 14,689 $ 14,703 Addition from acquisitions 251 — Currency translation adjustments (50) (14) Ending balance $ 14,890 $ 14,689
Schedule of identifiable intangible assets	Other intangible assets consisted of the following (in millions): December 31, 2021 2020 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 25,561 $ (12,769) $ 12,792 $ 25,591 $ (10,564) $ 15,027 Licensing rights 3,807 (2,973) 834 3,743 (2,791) 952 Marketing-related rights 1,354 (1,112) 242 1,367 (1,041) 326 R&D technology rights 1,377 (1,133) 244 1,317 (1,065) 252 Total finite-lived intangible assets 32,099 (17,987) 14,112 32,018 (15,461) 16,557 Indefinite-lived intangible assets: IPR&D 1,070 — 1,070 30 — 30 Total other intangible assets $ 33,169 $ (17,987) $ 15,182 $ 32,048 $ (15,461) $ 16,587

Leases - (Tables)

Leases - (Tables)	12 Months Ended
Leases - (Tables)	Dec. 31, 2021
Leases [Abstract]
Summary information, components of lease costs, cash and noncash information on leases and other lease information	The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): December 31, Consolidated Balance Sheets locations 2021 2020 Assets: Other noncurrent assets $ 566 $ 408 Liabilities: Accrued liabilities $ 145 $ 153 Other noncurrent liabilities 525 306 Total lease liabilities $ 670 $ 459 The components of net lease costs were as follows (in millions): Years ended December 31, Lease costs 2021 2020 2019 Operating (1) $ 237 $ 223 $ 204 Sublease income (38) (34) (33) Total net lease costs $ 199 $ 189 $ 171 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019. The weighted-average remaining lease terms and weighted-average discount rates were as follows: December 31, 2021 2020 Weighted-average remaining lease term (in years) 8.3 3.7 Weighted-average discount rate 2.5 % 3.1 % Cash and noncash information related to our leases was as follows (in millions): Years ended December 31, 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 190 $ 177 $ 148 ROU assets obtained in exchange for lease obligations: Operating leases $ 340 $ 101 $ 163
Maturities of lease liabilities	Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): Maturity dates Amounts 2022 $ 148 2023 148 2024 75 2025 49 2026 44 Thereafter 289 Total lease payments (1) 753 Less imputed interest (83) Present value of lease liabilities $ 670 ____________

Other current assets and accr_2

Other current assets and accrued liabilities (Tables)	12 Months Ended
Other current assets and accrued liabilities (Tables)	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following (in millions): December 31, 2021 2020 Prepaid expenses $ 1,223 $ 1,156 Corporate partner receivables 780 583 Tax receivables 164 216 Other 200 124 Total other current assets $ 2,367 $ 2,079
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in millions): December 31, 2021 2020 Sales deductions $ 5,174 $ 4,801 Dividends payable 1,083 1,018 Employee compensation and benefits 1,081 1,098 Income taxes payable 701 828 Sales returns reserve 542 474 Other 2,150 1,922 Total accrued liabilities $ 10,731 $ 10,141

Financing arrangements (Tables)

Financing arrangements (Tables)	12 Months Ended
Financing arrangements (Tables)	Dec. 31, 2021
Debt Disclosure [Abstract]
Carrying values and the fixed contractual coupon rates of long-term borrowings	Our borrowings consisted of the following (in millions): December 31, 2021 2020 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) — 1,527 2.70% notes due 2022 (2.70% 2022 Notes) — 500 2.65% notes due 2022 (2.65% 2022 Notes) — 1,500 3.625% notes due 2022 (3.625% 2022 Notes) — 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 767 791 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 500 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 853 916 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 643 649 2.20% notes due 2027 (2.20% 2027 Notes) 1,750 1,750 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 1.65% notes due in 2028 (1.65% 2028 Notes) 1,250 — 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 947 957 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 1,250 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 1,250 2.00% notes due 2032 (2.00% 2032 Notes) 1,250 — 6.375% notes due 2037 (6.375% 2037 Notes) 478 478 6.90% notes due 2038 (6.90% 2038 Notes) 254 254 6.40% notes due 2039 (6.40% 2039 Notes) 333 333 3.15% notes due 2040 (3.15% 2040 Notes) 2,000 2,000 5.75% notes due 2040 (5.75% 2040 Notes) 373 373 2.80% notes due 2041 (2.80% 2041 Notes) 1,150 — 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 729 729 5.65% notes due 2042 (5.65% 2042 Notes) 415 415 5.375% notes due 2043 (5.375% 2043 Notes) 185 185 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 2,250 2,250 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 3.00% notes due 2052 (3.00% 2052 Notes) 1,350 — 2.77% notes due 2053 (2.77% 2053 Notes) 940 940 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (1,213) (1,188) Fair value adjustments 284 566 Other 15 5 Total carrying value of debt 33,309 32,986 Less current portion (87) (91) Total long-term debt $ 33,222 $ 32,895
Schedule of interest rate derivatives	The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2021 December 31, 2020 Notes Notional amounts Effective interest rates Notional amounts Effective interest rates 3.625% 2022 Notes $ — N/A $ 750 LIBOR + 2.7% 3.625% 2024 Notes 1,400 LIBOR + 3.2% 1,400 LIBOR + 3.2% 3.125% 2025 Notes 1,000 LIBOR + 1.8% 1,000 LIBOR + 1.8% 2.60% 2026 Notes 1,250 LIBOR + 1.8% 1,250 LIBOR + 1.8% 2.45% 2030 Notes 1,000 LIBOR + 1.0% — N/A 2.30% 2031 Notes 500 LIBOR + 0.8% — N/A 4.663% 2051 Notes 1,500 LIBOR +4.1% 1,500 LIBOR + 4.1% Total notional amounts $ 6,650 $ 5,900 N/A = not applicable
Schedule of Long-term Debt Instruments Exchanged	The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions): Principal amount exchanged 6.375% 2037 Notes $ 74 6.90% 2038 Notes $ 37 6.40% 2039 Notes $ 133 5.75% 2040 Notes $ 39 5.15% 2041 Notes $ 245 5.65% 2042 Notes $ 72 5.375% 2043 Notes $ 76
Aggregate contractual maturities of long-term debt obligations	The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions): Maturity dates Amounts 2022 $ — 2023 1,517 2024 1,400 2025 1,500 2026 2,746 Thereafter 27,075 Total $ 34,238

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
Stockholders' equity (Tables)	Dec. 31, 2021
Equity [Abstract]
Summary of activity under our stock repurchase program	Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): Years ended December 31, 2021 2020 2019 Shares Dollars Shares Dollars Shares* Dollars First quarter 3.7 $ 865 4.3 $ 933 15.9 $ 3,031 Second quarter 6.5 1,592 2.6 591 13.1 2,349 Third quarter 4.6 1,069 3.0 752 6.2 1,170 Fourth quarter 6.9 1,461 5.3 1,221 5.1 1,090 Total stock repurchases 21.7 $ 4,987 15.2 $ 3,497 40.2 $ 7,640 * Total shares do not add due to rounding.
Components of accumulated other comprehensive income	The components of AOCI were as follows (in millions): Foreign Cash flow Available-for-sale Other AOCI Balance as of December 31, 2018 $ (670) $ 241 $ (338) $ (2) $ (769) Foreign currency translation adjustments (48) — — — (48) Unrealized gains — 127 424 — 551 Reclassification adjustments to income — (211) (56) — (267) Other losses — — — (5) (5) Income taxes — 18 (8) — 10 Balance as of December 31, 2019 (718) 175 22 (7) (528) Foreign currency translation adjustments 9 — — — 9 Unrealized (losses) gains — (61) 6 — (55) Reclassification adjustments to income — (501) (33) — (534) Other losses — — — (7) (7) Income taxes — 124 6 — 130 Balance as of December 31, 2020 (709) (263) 1 (14) (985) Foreign currency translation adjustments (135) — — — (135) Unrealized gains (losses) — 159 (1) — 158 Reclassification adjustments to income — 253 — — 253 Other gains — — — 1 1 Income taxes — (88) — — (88) Balance as of December 31, 2021 $ (844) $ 61 $ — $ (13) $ (796)
Reclassifications out of accumulated other comprehensive income	Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2021 2020 2019 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract (losses) gains $ (8) $ 178 $ 101 Product sales Cross-currency swap contract (losses) gains (245) 323 110 Other income, net (253) 501 211 Income before income taxes 55 (110) (46) Provision for income taxes $ (198) $ 391 $ 165 Net income Available-for-sale securities: Net realized gains $ — $ 33 $ 56 Other income, net — (7) (14) Provision for income taxes $ — $ 26 $ 42 Net income

Fair value measurement - (Table

Fair value measurement - (Tables)	12 Months Ended
Fair value measurement - (Tables)	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2021, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury notes $ 47 $ — $ — $ 47 U.S. Treasury bills 1,400 — — 1,400 Money market mutual funds 5,856 — — 5,856 Other short-term interest-bearing securities — 1 — 1 Equity securities 611 — 220 831 Derivatives: Foreign currency contracts — 183 — 183 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 16 — 16 Total assets $ 7,914 $ 266 $ 220 $ 8,400 Liabilities: Derivatives: Foreign currency contracts $ — $ 39 $ — $ 39 Cross-currency swap contracts — 339 — 339 Interest rate swap contracts — 156 — 156 Contingent consideration obligations — — 342 342 Total liabilities $ — $ 534 $ 342 $ 876 Fair value measurement as of December 31, 2020, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury notes $ 130 $ — $ — $ 130 U.S. Treasury bills 4,948 — — 4,948 Money market mutual funds 4,765 — — 4,765 Other short-term interest-bearing securities — 2 — 2 Equity securities 477 — — 477 Derivatives: Foreign currency contracts — 28 — 28 Cross-currency swap contracts — 255 — 255 Interest rate swap contracts — 66 — 66 Total assets $ 10,320 $ 351 $ — $ 10,671 Liabilities: Derivatives: Foreign currency contracts $ — $ 237 $ — $ 237 Cross-currency swap contracts — 318 — 318 Interest rate swap contracts — 15 — 15 Contingent consideration obligations — — 33 33 Total liabilities $ — $ 570 $ 33 $ 603
Changes in contingent consideration	Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): Years ended December 31, 2021 2020 2019 Beginning balance $ 33 $ 61 $ 72 Additions 309 — — Payments (7) (6) — Net changes in valuations 7 (22) (11) Ending balance $ 342 $ 33 $ 61

Derivative instruments - (Table

Derivative instruments - (Tables)	12 Months Ended
Derivative instruments - (Tables)	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 %
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2021 2020 2019 Foreign currency contracts $ 373 $ (251) $ 148 Cross-currency swap contracts (214) 190 (21) Total unrealized gains (losses) $ 159 $ (61) $ 127
Derivatives in fair value hedging relationships	The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2021 2020 2021 2020 Current portion of long-term debt $ 85 $ 89 $ 85 $ 89 Long-term debt $ 6,729 $ 6,258 $ 199 $ 477 ____________ (1) Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. (2) Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.
Summary of amounts of income and expense line items	The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2021 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,297 $ 259 $ (1,197) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ (8) $ — $ — Cross-currency swap contracts $ — $ (245) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 281 Derivatives designated as hedging instruments $ — $ — $ (192) Year ended December 31, 2020 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,240 $ 256 $ (1,262) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 178 $ — $ — Cross-currency swap contracts $ — $ 323 $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 315 Derivatives designated as hedging instruments $ — $ — $ (204) Year ended December 31, 2019 Product sales Other income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,204 $ 753 $ (1,289) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 101 $ — $ — Cross-currency swap contracts $ — $ 110 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (349) Derivatives designated as hedging instruments $ — $ — $ 352 __________
Fair values of derivatives included in the Consolidated Balance Sheets	The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2021 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other noncurrent assets $ 183 Accrued liabilities/ Other noncurrent liabilities $ 39 Cross-currency swap contracts Other current assets/ Other noncurrent assets 66 Accrued liabilities/ Other noncurrent liabilities 339 Interest rate swap contracts Other current assets/ Other noncurrent assets 16 Accrued liabilities/ Other noncurrent liabilities 156 Total derivatives designated as hedging instruments 265 534 Total derivatives $ 265 $ 534 Derivative assets Derivative liabilities December 31, 2020 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other noncurrent assets $ 28 Accrued liabilities/ Other noncurrent liabilities $ 237 Cross-currency swap contracts Other current assets/ Other noncurrent assets 255 Accrued liabilities/ Other noncurrent liabilities 318 Interest rate swap contracts Other current assets/ Other noncurrent assets 66 Accrued liabilities/ Other noncurrent liabilities 15 Total derivatives designated as hedging instruments 349 570 Total derivatives $ 349 $ 570

Contingencies and commitments -

Contingencies and commitments - (Tables)	12 Months Ended
Contingencies and commitments - (Tables)	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
U.S. repatriation tax commitments	The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions): Amounts 2022 $ 587 2023 1,100 2024 1,467 2025 1,834 Total remaining U.S. repatriation tax commitments $ 4,988

Summary of significant accoun_3

Summary of significant accounting policies - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of business segment \| segment	1
Sales return provisions as a percentage of gross product sales (less than)	1.00%
Advertising cost \| $	$ 843	$ 962	$ 789
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term	30 days
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term	120 days

Acquisitions - Aggregate Consid

Acquisitions - Aggregate Consideration Paid (Details) - USD ($) $ in Millions	Oct. 19, 2021	Nov. 21, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Additions			$ 309	$ 0	$ 0
Goodwill			$ 14,890	$ 14,689	$ 14,703
Teneobio
Business Acquisition [Line Items]
Cash paid	$ 994
Additions	309
Business asset acquisition, consideration transferred	1,303
Cash and cash equivalents	100
Goodwill	251
Other assets, net	16
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	(253)
Total assets acquired, net	1,303
Teneobio \| R & D Technology rights
Business Acquisition [Line Items]
Finite-lived intangible assets	94
Teneobio \| Licensing rights
Business Acquisition [Line Items]
Finite-lived intangible assets	41
Teneobio \| IPR&D
Business Acquisition [Line Items]
IPR&D	$ 1,054
Otezla
Business Acquisition [Line Items]
Cash paid		$ 13,400
Transaction costs		40
Business asset acquisition, consideration transferred		13,440
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities		(24)
Deferred credit		(96)
Other liabilities, net		(9)
Inventory		367
Total assets acquired, net		13,440
Otezla \| Developed Technology Rights
Business Acquisition [Line Items]
Finite-lived intangible assets		13,007
Otezla \| Marketing-Related Rights
Business Acquisition [Line Items]
Finite-lived intangible assets		$ 195

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Millions	Oct. 19, 2021USD ($)	Apr. 16, 2021USD ($)	Nov. 21, 2019USD ($)	Jul. 15, 2019USD ($)	Dec. 31, 2021USD ($)market	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Business Acquisition [Line Items]
Estimated fair values of contingent consideration obligations					$ 309	$ 0	$ 0
Goodwill					14,890	14,689	14,703
Cash paid for acquisitions, net of cash acquired					2,529	0	13,617
Acquired in-process research and development					$ 1,505	$ 0	$ 0
Estimated blended statutory rate			20.00%
Teneobio
Business Acquisition [Line Items]
Cash paid	$ 994
Maximum additional consideration due contingent on certain milestones	1,600
Estimated fair values of contingent consideration obligations	309
Fair value of liabilities assumed, deferred tax liabilities	253
Goodwill	251
Fair value of assets acquired and liabilities assumed, net other assets and liabilities	16
Teneobio \| R & D Technology rights
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 94
Weighted average period of amortization	10 years
Teneobio \| Licensing rights
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 41
Teneobio \| IPR&D
Business Acquisition [Line Items]
Acquired in-process research and development	1,054
Teneobio \| IPR&D \| AMG 340
Business Acquisition [Line Items]
Acquired in-process research and development	$ 784
Five Prime Therapeutics, Inc.
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired		$ 1,600
Acquired in-process research and development		1,500
Deferred tax assets		177
Other liabilities		$ 47
Otezla
Business Acquisition [Line Items]
Cash paid			$ 13,400
Fair value of liabilities assumed, deferred tax liabilities			24
Approved markets \| market					50
Adjustments to carrying value of intangible assets			119
Adjustments to deferred tax liability			24
Adjustments to deferred credit			$ 96
Otezla \| Inventories
Business Acquisition [Line Items]
Acquired assets, weighted useful life					2 years 6 months
Otezla \| Developed Technology Rights
Business Acquisition [Line Items]
Weighted average period of amortization			8 years 6 months
Otezla \| Marketing-Related Rights \| Assembled Workforce
Business Acquisition [Line Items]
Weighted average period of amortization			5 years
Nuevolution
Business Acquisition [Line Items]
Fair value of liabilities assumed, deferred tax liabilities				$ 22
Goodwill				26
Consideration transferred				183
Fair value of assets acquired and liabilities assumed, net other assets and liabilities				29
Nuevolution \| R & D Technology rights
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired				$ 150
Weighted average period of amortization				10 years

Revenues - Narrative (Details)

Revenues - Narrative (Details) $ in Millions	12 Months Ended
Revenues - Narrative (Details) $ in Millions	Dec. 31, 2021USD ($)segmentcustomer	Dec. 31, 2020USD ($)customer	Dec. 31, 2019USD ($)customer
Revenue from Contract with Customer [Abstract]
Number of operating segments \| segment	1
Revenue from External Customer [Line Items]
Number of major customers (as defined) accounting for more than 10% of total revenue \| customer	3	3	3
Major customers (as defined) accounting for more than 10% of gross trade receivables \| customer	3	3
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables	73.00%	74.00%
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis	82.00%
Total product sales	$ 25,979	$ 25,424	$ 23,362
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe	27.00%	28.00%
US [Member]
Revenue from External Customer [Line Items]
Total product sales	$ 18,194	$ 18,496	17,224
ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	7,785	6,928	6,138
Product sales
Revenue from External Customer [Line Items]
Total product sales	24,297	24,240	22,204
Product sales \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	17,286	17,985	16,531
Product sales \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	7,011	6,255	5,673
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales	4,465	4,996	5,226
Enbrel® (etanercept) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	4,352	4,855	5,050
Enbrel® (etanercept) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	113	141	176
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	3,248	2,763	2,672
Prolia® (denosumab) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	2,150	1,830	1,772
Prolia® (denosumab) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,098	933	900
Otezla [Member]
Revenue from External Customer [Line Items]
Total product sales	2,249	2,195	178
Otezla [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,804	1,790	139
Otezla [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	445	405	39
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	2,018	1,899	1,935
XGEVA® (denosumab) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,434	1,405	1,457
XGEVA® (denosumab) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	584	494	478
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,734	2,293	3,221
Neulasta® (pegfilgrastim) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,514	2,001	2,814
Neulasta® (pegfilgrastim) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	220	292	407
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,480	1,568	1,729
Aranesp® (darbepoetin alfa) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	537	629	758
Aranesp® (darbepoetin alfa) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	943	939	971
Repatha (evolocumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,117	887	661
Repatha (evolocumab) [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	557	459	376
Repatha (evolocumab) [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	560	428	285
Kyprolis [Member]
Revenue from External Customer [Line Items]
Total product sales	1,108	1,065	1,044
Kyprolis [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	736	710	654
Kyprolis [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	372	355	390
Nplate
Revenue from External Customer [Line Items]
Total product sales	1,027	850	795
Nplate \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	566	485	480
Nplate \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	461	365	315
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	5,851	5,724	4,743
Other products [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	3,636	3,821	3,031
Other products [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	2,215	1,903	1,712
Other revenues [Member]
Revenue from External Customer [Line Items]
Total product sales	1,682	1,184	1,158
Other revenues [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	908	511	693
Other revenues [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	774	673	465
AmerisourceBergen Corporation [Member] \| Product sales
Revenue from External Customer [Line Items]
Total product sales	14,783	14,743	12,301
McKesson Corporation [Member] \| Product sales
Revenue from External Customer [Line Items]
Total product sales	15,187	13,779	11,795
Cardinal Health, Inc. [Member] \| Product sales
Revenue from External Customer [Line Items]
Total product sales	$ 7,681	$ 7,332	$ 6,538

Revenues - Customer Concentrati

Revenues - Customer Concentration, Product Sales (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)customer	Dec. 31, 2020USD ($)customer	Dec. 31, 2019USD ($)customer
Revenue, Major Customer [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 25,979	$ 25,424	$ 23,362
Number of major customers (as defined) accounting for more than 10% of total revenue \| customer	3	3	3
Major customers (as defined) accounting for more than 10% of gross trade receivables \| customer	3	3
Product [Member]
Revenue, Major Customer [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 24,297	$ 24,240	$ 22,204
Product [Member] \| AmerisourceBergen Corporation [Member]
Revenue, Major Customer [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 14,783	$ 14,743	$ 12,301
Gross product sales to major customer (as defined) as a percentage of total gross revenues	32.00%	34.00%	33.00%
Product [Member] \| McKesson Corporation [Member]
Revenue, Major Customer [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 15,187	$ 13,779	$ 11,795
Gross product sales to major customer (as defined) as a percentage of total gross revenues	33.00%	32.00%	31.00%
Product [Member] \| Cardinal Health, Inc. [Member]
Revenue, Major Customer [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 7,681	$ 7,332	$ 6,538
Gross product sales to major customer (as defined) as a percentage of total gross revenues	17.00%	17.00%	17.00%

Stock-based compensation (Textu

Stock-based compensation (Textual) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount by which the pool of available shares will be reduced for each stock option granted	1
The amount of common stock available under the plan for future grants and/or issuances (in shares)	19,000,000
Description of vesting of restricted stock units and stock options	RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.
Total unrecognized compensation cost related to nonvested awards	$ 346
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized	1 year 9 months 18 days
Period over which the grants of equity instruments vest	3 years
Number of common shares issued for each performance unit earned	1	1	1
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9
Number of shares added back for tax withholding on full value awards	1.9
Weighted average grant date fair value, granted (in usd per share)	$ 233.10	$ 235.63	$ 182.12
Total fair value of units that vested during the year	$ 166	$ 161	$ 160
Units outstanding (in shares)	3,000,000	3,000,000
Weighted-average grant date fair value	$ 217.95	$ 198.11
Units granted (in shares)	1,300,000
Units, forfeited (in shares)	400,000
Weighted average grant date fair value, forfeited (in usd per share)	$ 213.32
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of stock options from date of grant	10 years
Total intrinsic value of stock options exercised during the year	$ 56	$ 98	68
Actual tax benefits realized from tax deductions from option exercises	$ 12	$ 21	$ 15
Performance units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9
Number of shares added back for tax withholding on full value awards	1.9
Weighted average grant date fair value, granted (in usd per share)	$ 254.68	$ 249.07	$ 188.40
Total fair value of units that vested during the year	$ 149	$ 230	$ 176
Total unrecognized compensation cost related to nonvested awards	$ 130
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized	1 year
Units outstanding (in shares)	1,600,000	1,800,000
Weighted-average grant date fair value	$ 229.39	$ 207.52
Units granted (in shares)	600,000
Units, forfeited (in shares)	200,000
Weighted average grant date fair value, forfeited (in usd per share)	$ 226.32

Stock-based compensation (Compo

Stock-based compensation (Components of Stock-based Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 341	$ 330	$ 308
Tax benefit from stock-based compensation expense	(74)	(72)	(67)
Total stock-based compensation expense, net of tax	267	258	241
RSUs [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	183	178	168
Performance units [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	121	118	105
Stock options [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 37	$ 34	$ 35

Stock-based compensation (Summa

Stock-based compensation (Summary of RSUs) (Details) - RSUs [Member] - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Units
Balance nonvested at beginning of period (in shares)	3
Granted (in shares)	1.3
Vested (in shares)	(0.9)
Forfeited (in shares)	(0.4)
Balance nonvested at end of period (in shares)	3	3
Weighted-average grant date fair value
Balance nonvested at beginning of period (in usd per share)	$ 198.11
Granted (in usd per share)	233.10	$ 235.63	$ 182.12
Vested (in usd per share)	177.27
Forfeited (in usd per share)	213.32
Balance nonvested at end of period (in usd per share)	$ 217.95	$ 198.11

Stock-based compensation Stock-

Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of our common stock on grant date (in usd per share)	$ 237.17	$ 236.36	$ 177.31
Volatility	25.60%	28.10%	23.50%
Expected life (in years)	5 years 8 months 12 days	5 years 9 months 18 days	5 years 9 months 18 days
Risk-free interest rate	1.00%	0.40%	2.40%
Expected dividend yield	2.90%	3.00%	3.10%
Granted (in usd per share)	$ 40.43	$ 42.34	$ 30.47

Stock-based compensation (Sum_2

Stock-based compensation (Summary of Stock Options) (Details) - Stock options [Member] $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Options
Balance unexercised at beginning of period (in shares) \| shares	4.7
Granted (in shares) \| shares	1.3
Exercised (in shares) \| shares	(0.5)
Expired/forfeited (in shares) \| shares	(0.4)
Balance unexercised at end of period (in shares) \| shares	5.1
Vested or expected to vest (in shares) \| shares	4.9
Exercisable (in shares) \| shares	2
Weighted- average exercise price
Balance unexercised at beginning of period (in usd per share) \| $ / shares	$ 179.90
Granted (in usd per share) \| $ / shares	237.17
Exercised (in usd per share) \| $ / shares	137.95
Expired/forfeited (in usd per share) \| $ / shares	208.56
Balance unexercised at end of period (in shares) \| $ / shares	197.27
Weighted-average exercise price, vested or expected to vest (in usd per share) \| $ / shares	195.64
Weighted-average exercise price, exercisable (in usd per share) \| $ / shares	$ 165.46
Stock options information [Abstract]
Weighted-average remaining contractual life (years), unexercised	7 years 3 months 18 days
Weighted-average remaining contractual life (years), vested or expected to vest	7 years 2 months 12 days
Weighted-average remaining contractual life (years), exercisable	5 years 7 months 6 days
Aggregate intrinsic value, unexercised \| $	$ 168
Aggregate intrinsic value, vested or expected to vest \| $	167
Aggregate intrinsic value, exercisable \| $	$ 120

Stock-based compensation (Weigh

Stock-based compensation (Weighted-average Assumptions) (Details) - Performance units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]
Closing price of our common stock on grant date (in usd per share)	$ 239.64	$ 236.36	$ 177.31
Volatility	29.30%	27.50%	22.10%
Risk-free interest rate	0.30%	0.20%	2.30%
Fair value of unit (in usd per share)	$ 254.68	$ 249.07	$ 188.40

Defined contribution plan (Deta

Defined contribution plan (Details) - USD ($) $ in Millions	12 Months Ended
Defined contribution plan (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Expense attributed to Retirement and Savings Plan	$ 279	$ 231	$ 220

Income taxes (Income Before Inc

Income taxes (Income Before Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Examination [Line Items]
Income before income taxes	$ 6,701	$ 8,133	$ 9,138
Domestic [Member]
Income Tax Examination [Line Items]
Income before income taxes	1,850	4,087	4,371
Foreign [Member]
Income Tax Examination [Line Items]
Income before income taxes	$ 4,851	$ 4,046	$ 4,767

Income taxes (Provision for Inc

Income taxes (Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current provision:
Federal	$ 865	$ 921	$ 1,284
State	18	34	39
Foreign	359	277	277
Total current provision	1,242	1,232	1,600
Deferred benefit:
Federal	(308)	(321)	(276)
State	(9)	9	(22)
Foreign	(117)	(51)	(6)
Total deferred benefit	(434)	(363)	(304)
Total provision for income taxes	$ 808	$ 869	$ 1,296

Income taxes (Components of Def

Income taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred income tax assets:
NOL and credit carryforwards	$ 1,065	$ 794
Accrued expenses	600	561
Expenses capitalized for tax	244	144
Stock-based compensation	96	92
Other	326	301
Total deferred income tax assets	2,331	1,892
Valuation allowance	(663)	(571)
Net deferred income tax assets	1,668	1,321
Deferred income tax liabilities:
Acquired intangible assets	(824)	(903)
Debt	(275)	(282)
Deferred Tax Liabilities, Property, Plant and Equipment	(129)	(148)
Other	(221)	(189)
Total deferred income tax liabilities	(1,449)	(1,522)
Total deferred income taxes, net	$ 219
Total deferred income taxes, net		$ (201)

Income taxes (Textual) (Details

Income taxes (Textual) (Details)	12 Months Ended
Income taxes (Textual) (Details)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	May 31, 2021USD ($)
Tax Credit Carryforward [Line Items]
Interest and penalties related to unrecognized tax benefits recognized in income tax provision	$ 98,000,000	$ 116,000,000	$ 198,000,000
Accrued interest and penalties associated with unrecognized tax benefits	881,000,000	783,000,000
Income taxes paid	1,900,000,000	$ 1,400,000,000	$ 1,900,000,000
Federal [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	75,000,000
NOL carryforwards available to reduce income taxes	606,000,000
NOL carryforwards, valuation allowance	6,000,000
NOLs with no valuation allowance and no expiration	426,000,000
Proposed additional income tax				$ 3,600,000,000
Repatriation tax on proposed additional tax				$ 900,000,000
Number of notices on proposed additional tax				2
Federal [Member] \| Expiration in tax years between 2023 and 2040
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, valuation allowance	0
Federal [Member] \| Operating Losses That Expire Between 2022 and 2037
Tax Credit Carryforward [Line Items]
NOL carryforwards, valuation allowance	0
State [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	798,000,000
Tax credit carryforwards, valuation allowance	709,000,000
NOL carryforwards available to reduce income taxes	391,000,000
NOL carryforwards, valuation allowance	330,000,000
Foreign [Member]
Tax Credit Carryforward [Line Items]
NOL carryforwards available to reduce income taxes	2,000,000,000
NOL carryforwards, valuation allowance	561,000,000
NOLs with no valuation allowance and no expiration	800,000,000
Foreign [Member] \| Operating Losses That Expire Between 2022 and 2031
Tax Credit Carryforward [Line Items]
NOL carryforwards, valuation allowance	$ 0

Income taxes (Reconciliation of

Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)
Beginning balance	$ 3,352	$ 3,287	$ 3,061
Additions based on tax positions related to the current year	171	165	215
Additions based on tax positions related to prior years	35	3	22
Reductions for tax positions of prior years	(4)	(35)	(11)
Settlements	(8)	(68)	0
Ending balance	$ 3,546	$ 3,352	$ 3,287

Income taxes (Reconciliation _2

Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%	21.00%	21.00%
Foreign earnings	(7.80%)	(4.70%)	(4.50%)
Foreign-derived intangible income	(1.00%)	(0.70%)	(0.70%)
Credits, Puerto Rico excise tax	(3.40%)	(2.90%)	(2.60%)
Interest on uncertain tax positions	1.10%	1.10%	1.60%
Credits, primarily federal R&D	(2.10%)	(1.40%)	(1.00%)
Acquisition IPR&D	4.90%	0.00%	0.00%
Audit settlements	0.00%	(1.00%)	0.00%
Other, net	(0.60%)	(0.70%)	0.40%
Effective tax rate	12.10%	10.70%	14.20%

Earnings per share (Details)

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income (Numerator):
Net income for basic and diluted EPS	$ 5,893	$ 7,264	$ 7,842
Shares (Denominator):
Weighted-average shares for basic EPS	570	586	605
Effect of dilutive securities (in shares)	3	4	4
Weighted-average shares for diluted EPS	573	590	609
Basic EPS (in usd per share)	$ 10.34	$ 12.40	$ 12.96
Diluted EPS (in usd per share)	$ 10.28	$ 12.31	$ 12.88

Collaborations - Novartis AG (D

Collaborations - Novartis AG (Details) - Collaborative Arrangement with Novartis AG [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential future milestone payment	$ 100
Selling, general and administrative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost recoveries	160	$ 192	$ 187
Cost of sales [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties due	$ 116	$ 139	$ 115

Collaborations - BeiGene (Detai

Collaborations - BeiGene (Details) - USD ($)	Jan. 02, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		$ 25,979,000,000	$ 25,424,000,000	$ 23,362,000,000
BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership percentage	20.50%	18.40%	20.50%
Equity Method Investment, Aggregate Cost	$ 2,800,000,000
BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross	$ 1,250,000,000
BeiGene \| Other current assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related Party Transaction, Due from (to) Related Party		$ 61,000,000	$ 99,000,000
BeiGene \| Trade Accounts Receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related Party Transaction, Due from (to) Related Party		21,000,000	22,000,000
BeiGene \| Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost recoveries		220,000,000	$ 225,000,000
BeiGene \| Selling, general and administrative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit and loss share of expenses		64,000,000
BeiGene \| BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		$ 72,000,000

Collaborations - Kyowa Kirin (D

Collaborations - Kyowa Kirin (Details) - Kyowa Kirin Co. Ltd. - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment	$ 400
Revenue Recognition, Milestone Method, Potential Future Milestone payments		$ 850

Investments - Schedule (Details

Investments - Schedule (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt securities
Amortized cost	$ 7,304	$ 9,844
Gross unrealized gains	0	1
Gross unrealized losses	0	0
Fair values	7,304	9,845
U.S. Treasury notes [Member]
Debt securities
Amortized cost	47	129
Gross unrealized gains	0	1
Gross unrealized losses	0	0
Fair values	47	130
U.S. Treasury bills [Member]
Debt securities
Amortized cost	1,400	4,948
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	1,400	4,948
Money market mutual funds [Member]
Debt securities
Amortized cost	5,856	4,765
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	5,856	4,765
Other short-term interest-bearing securities [Member]
Debt securities
Amortized cost	1	2
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 1	$ 2

Investments - Fair Values by Cl

Investments - Fair Values by Classification (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets locations
Marketable securities	$ 48	$ 4,381
Total available-for-sale investments	7,304	9,845
Available-for-sale investments [Member]
Consolidated Balance Sheets locations
Cash and cash equivalents	7,256	5,464
Marketable securities	48	4,381
Total available-for-sale investments	$ 7,304	$ 9,845

Investments - Available-for-sal

Investments - Available-for-sale (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020
Gain (Loss) on Securities [Line Items]
Cash		$ 733	$ 802
Nonoperating Income (Expense)
Gain (Loss) on Securities [Line Items]
Total realized gains	$ 92

Investments - Fair Values by Co

Investments - Fair Values by Contractual Maturity (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 7,304	$ 9,795
Maturing after one year through three years	0	50
Total available-for-sale investments	$ 7,304	$ 9,845

Investments - Equity Securities

Investments - Equity Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities	$ 831	$ 477
Equity Securities, FV-NI, Unrealized Gain (Loss)	161	174	$ 112
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	152
Equity Securities, Realized Gain (Loss) on Disposal	41
Other Noncurrent Assets
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities	611	477
Equity securities without readily determinable fair value	$ 262	$ 203

Investments - Limited Partnersh

Investments - Limited Partnership Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net Investment Income [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Amount	$ 185
Limited Partnership [Member] \| Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	573	$ 496
Alternative Investment, Net Gain (Loss)	$ 143	$ 241	$ 27

Investments - BeiGene (Details)

Investments - BeiGene (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2020
Net Investment Income [Line Items]
Payments to Acquire Equity Method Investments			$ 157	$ 3,219	$ 24
BeiGene
Net Investment Income [Line Items]
Ownership percentage		18.40%	18.40%	20.50%		20.50%
Equity Method Investment, Aggregate Cost						$ 2,800
Equity Method Investment, Quoted Market Value		$ 5,100	$ 5,100	$ 4,900		2,600
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity						2,400
Payments to Acquire Equity Method Investments			50	569
Equity Method Investment, Change In Carrying Value, Other			265	34
Company's share of profits (losses) of related party			265	229
Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity			172	109
Approximate carrying value of the company's equity method investment		2,800	2,800	2,900
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Method Investment, Quoted Market Value		$ 5,100	$ 5,100	$ 4,900		$ 2,600
BeiGene \| Minimum [Member]
Net Investment Income [Line Items]
Finite-Lived Intangible Asset, Useful Life			8 years
BeiGene \| Maximum [Member]
Net Investment Income [Line Items]
Finite-Lived Intangible Asset, Useful Life			15 years
Neumora Therapeutics, Inc.
Net Investment Income [Line Items]
Ownership percentage	25.90%	25.90%	25.90%
Equity Method Investment, Aggregate Cost	$ 257
Equity method investment, change in carrying value		$ 37
Payments to Acquire Equity Method Investments	$ 100

Investments - Neumora Therapeut

Investments - Neumora Therapeutics, Inc. (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Payments to Acquire Equity Method Investments		$ 157	$ 3,219	$ 24
Neumora Therapeutics, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage	25.90%	25.90%
Equity Method Investment, Aggregate Cost	$ 257
Payments to Acquire Equity Method Investments	100
Noncash or Part Noncash Acquisition, Investments Acquired	$ 157
Equity Method Investments, Fair Value Disclosure		$ 220

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 647	$ 486
Work in process	2,367	2,437
Finished goods	1,072	970
Total inventories	$ 4,086	$ 3,893

Property, plant and equipment_2

Property, plant and equipment (Schedule) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Land	$ 279	$ 259
Buildings and improvements	4,028	3,857
Manufacturing equipment	3,080	2,865
Laboratory equipment	1,193	1,257
Fixed equipment	2,402	2,406
Capitalized software	1,151	1,216
Other	862	1,091
Construction in progress	987	915
Property, plant and equipment, gross	13,982	13,866
Less accumulated depreciation and amortization	(8,798)	(8,977)
Property, plant and equipment, net	5,184	4,889
Depreciation and amortization charges associated with property, plant and equipment	$ 644	$ 640	$ 635
Buildings and improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Buildings and improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	40 years
Manufacturing equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Manufacturing equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Laboratory equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Laboratory equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Fixed equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Capitalized software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Capitalized software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Other [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Other [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years

Property, plant and equipment_3

Property, plant and equipment (Geographic Information) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 5,184	$ 4,889
US [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	2,801	2,473
Puerto Rico [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	1,311	1,331
ROW [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 1,072	$ 1,085

Goodwill and other intangible_2

Goodwill and other intangible assets - Goodwill Roll Forward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Beginning balance	$ 14,689	$ 14,703
Addition from acquisitions	251	0
Currency translation adjustments	(50)	(14)
Ending balance	$ 14,890	$ 14,689

Goodwill and other intangible_3

Goodwill and other intangible assets - Identifiable Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finite-lived intangible assets:
Gross carrying amounts	$ 32,099	$ 32,018
Accumulated amortization	(17,987)	(15,461)
Other intangible assets, net	14,112	16,557
Indefinite-lived intangible assets:
Identifiable intangible assets	33,169	32,048
Accumulated amortization	(17,987)	(15,461)
Identifiable intangible assets, net	15,182	16,587
IPR&D
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	1,070	30
Developed Technology Rights
Finite-lived intangible assets:
Gross carrying amounts	25,561	25,591
Accumulated amortization	(12,769)	(10,564)
Other intangible assets, net	12,792	15,027
Licensing rights
Finite-lived intangible assets:
Gross carrying amounts	3,807	3,743
Accumulated amortization	(2,973)	(2,791)
Other intangible assets, net	834	952
Marketing-related rights [Member]
Finite-lived intangible assets:
Gross carrying amounts	1,354	1,367
Accumulated amortization	(1,112)	(1,041)
Other intangible assets, net	242	326
R&D technology rights [Member]
Finite-lived intangible assets:
Gross carrying amounts	1,377	1,317
Accumulated amortization	(1,133)	(1,065)
Other intangible assets, net	$ 244	$ 252

Goodwill and other intangible_4

Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization charges associated with finite-lived intangible assets	$ 2,600	$ 2,800	$ 1,400
Total estimated amortization of finite-lived intangible assets for 2022	2,500
Total estimated amortization of finite-lived intangible assets for 2023	2,500
Total estimated amortization of finite-lived intangible assets for 2024	2,400
Total estimated amortization of finite-lived intangible assets for 2025	2,200
Total estimated amortization of finite-lived intangible assets for 2026	1,800
Teneobio, Inc. \| IPR&D
Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	1,100
Teneobio, Inc. \| Developed Technology Rights
Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	94
Teneobio, Inc. \| Favorable Contract
Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 41

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Renewal term	7 years
Weighted-average remaining lease term (in years)	8 years 3 months 18 days	3 years 8 months 12 days
Weighted-average discount rate	2.50%	3.10%
Total undiscounted future lease payment	$ 35
Total lease payments	$ 753
Minimum [Member]
Lessee, Lease, Description [Line Items]
Leases not yet commenced lease term	4 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Leases not yet commenced lease term	6 years

Leases - Summary of Leases (Det

Leases - Summary of Leases (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets:
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Other assets	$ 566	$ 408
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current	Accrued Liabilities, Current
Liabilities:
Accrued liabilities	$ 145	$ 153
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Other noncurrent liabilities	$ 525	$ 306
Total lease liabilities	$ 670	$ 459

Leases - Components of Lease Co

Leases - Components of Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating	$ 237	$ 223	$ 204
Sublease income	(38)	(34)	(33)
Total net lease costs	$ 199	$ 189	$ 171

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
2022	$ 148
2023	148
2024	75
2025	49
2026	44
Thereafter	289
Total lease payments	753
Less imputed interest	(83)
Present value of lease liabilities	670	$ 459
Abandoned Leases [Member]
Lessee, Lease, Description [Line Items]
Future rental commitments for abandoned leases	138
Expected total future rental income to be received	$ 108

Leases - Cash and Noncash Infor

Leases - Cash and Noncash Information of Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 190	$ 177	$ 148
ROU assets obtained in exchange for lease obligations	$ 340	$ 101	$ 163

Other current assets and accr_3

Other current assets and accrued liabilities - Schedule of Other Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Prepaid expenses	$ 1,223	$ 1,156
Corporate partner receivables	780	583
Tax receivables	164	216
Other	200	124
Total other current assets	$ 2,367	$ 2,079

Other current assets and accr_4

Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Sales deductions	$ 5,174	$ 4,801
Dividends payable	1,083	1,018
Employee compensation and benefits	1,081	1,098
Income taxes payable	701	828
Sales returns reserve	542	474
Other	2,150	1,922
Total accrued liabilities	$ 10,731	$ 10,141

Financing arrangements (Princip

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021CHF (SFr)	Dec. 31, 2021EUR (€)	Dec. 31, 2021GBP (£)	Dec. 31, 2020USD ($)
Carrying values of long-term borrowings
Unamortized bond discounts, premiums and issuance costs, net	$ (1,213)				$ (1,188)
Fair value adjustments	284				566
Other Long-term Debt	15				5
Total carrying value of debt	33,309				32,986
Less current portion	(87)				(91)
Total long-term debt	$ 33,222				32,895
0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Notes [Member]
Debt Instrument [Line Items]
Face amount	$ 5,000				$ 9,000
Notes [Member] \| 1.25% 2022 euro Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%	1.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					$ 1,527
Notes [Member] \| 2.70% notes due 2022 (2.70% 2022 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 0				500
Notes [Member] \| 2.65% notes due 2022 (2.65% 2022 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 0				$ 1,500
Notes [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%	3.625%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					$ 750
Notes [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Face amount \| SFr		SFr 700,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 767				791
Notes [Member] \| 2.25% notes due 2023 (2.25% 2023 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 750				$ 750
Notes [Member] \| 3.625% notes due 2024 (3.625% 2024 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%	3.625%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,400				$ 1,400
Notes [Member] \| 1.90% notes due 2025 (1.90% 2025 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%	1.90%
Face amount					$ 500
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 500				$ 500
Notes [Member] \| 3.125% notes due 2025 (3.125% 2025 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%	3.125%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,000				$ 1,000
Notes [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Face amount \| €			€ 750,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 853				$ 916
Notes [Member] \| 2.60% notes due 2026 (2.60% 2026 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%	2.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250				$ 1,250
Notes [Member] \| 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Face amount \| £				£ 475,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 643				$ 649
Notes [Member] \| 2.20% notes due 2027 (2.20% 2027 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%	2.20%
Face amount					$ 1,750
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,750				1,750
Notes [Member] \| 3.20% notes due 2027 (3.20% 2027 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,000				1,000
Notes [Member] \| 1.65% notes due in 2028 (1.65% 2028 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	1.65%	1.65%	1.65%	1.65%
Face amount	$ 1,250
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250
Notes [Member] \| 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Face amount \| £				£ 700,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 947				$ 957
Notes [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%	2.45%	2.45%	2.45%
Face amount					$ 1,250
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250				$ 1,250
Notes [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%	2.30%	2.30%	2.30%	2.30%
Face amount					$ 1,250
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250				$ 1,250
Notes [Member] \| 2.00% notes due 2032 (2.00% 2032 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250
Notes [Member] \| 6.375% notes due 2037 (6.375% 2037 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%	6.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 478				$ 478
Notes [Member] \| 6.90% notes due 2038 (6.90% 2038 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%	6.90%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 254				$ 254
Notes [Member] \| 6.40% notes due 2039 (6.40% 2039 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%	6.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 333				$ 333
Notes [Member] \| 3.15% notes due 2040 (3.15% 2040 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%	3.15%	3.15%	3.15%
Face amount					$ 2,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 2,000				$ 2,000
Notes [Member] \| 5.75% notes due 2040 (5.75% 2040 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%	5.75%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 373				$ 373
Notes [Member] \| 2.80% notes due 2041 (2.80% 2041 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.80%	2.80%	2.80%	2.80%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,150
Notes [Member] \| 4.95% notes due 2041 (4.95% 2041 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 600				$ 600
Notes [Member] \| 5.15% notes due 2041 (5.15% 2041 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%	5.15%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 729				$ 729
Notes [Member] \| 5.65% notes due 2042 (5.65% 2042 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%	5.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 415				$ 415
Notes [Member] \| 5.375% notes due 2043 (5.375% 2043 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%	5.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 185				$ 185
Notes [Member] \| 4.40% notes due 2045 (4.40% 2045 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 2,250				2,250
Notes [Member] \| 4.563% notes due 2048 (4.563% 2048 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Effective interest rate on note	6.30%	6.30%	6.30%	6.30%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,415				$ 1,415
Notes [Member] \| 3.375% notes due 2050 (3.375% 2050 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%	3.375%	3.375%	3.375%
Face amount					$ 2,250
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 2,250				$ 2,250
Notes [Member] \| 4.663% notes due 2051 (4.663% 2051 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%	4.663%
Effective interest rate on note	5.60%	5.60%	5.60%	5.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 3,541				$ 3,541
Notes [Member] \| 3.00% notes due 2052 (3.00% 2052 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.00%	3.00%	3.00%	3.00%
Face amount	$ 1,350
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,350
Notes [Member] \| 2.77% notes due 2053 (2.77% 2053 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.77%	2.77%	2.77%	2.77%	2.77%
Face amount					$ 940
Effective interest rate on note	5.20%	5.20%	5.20%	5.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 940				940
Notes [Member] \| Other notes due 2097
Carrying values of long-term borrowings
Long-term debt, gross	$ 100				$ 100
Notes [Member] \| 4.10% notes due 2021 (4.10% 2021 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					4.10%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 2.125% notes due 2020 (2.125% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					2.125%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 3.45% notes due 2020 (3.45% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					3.45%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 1.85% notes due 2021 (1.85% 2021 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					1.85%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 4.50% notes due 2020 (4.50% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					4.50%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| Floating Rate Notes Due 2020
Debt Instrument [Line Items]
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 2.20% notes due 2020 (2.20% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					2.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Notes [Member] \| 3.875% notes due 2021 (3.875% 2021 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage					3.875%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Debt securities payable [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	1 month
Debt securities payable [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	6 months

Financing arrangements (Debt Is

Financing arrangements (Debt Issuances) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Commercial paper, maximum borrowing capacity	$ 2,500,000,000
Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	5,000,000,000	$ 9,000,000,000
Notes [Member] \| 1.65% notes due in 2028 (1.65% 2028 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 1,250,000,000
Interest rate, stated percentage	1.65%
Notes [Member] \| 2.00% notes due 2032 (2.00% 2032 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 1,250,000,000
Interest rate, stated percentage	2.00%
Notes [Member] \| 2.80% notes due 2041 (2.80% 2041 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 1,150,000,000
Interest rate, stated percentage	2.80%
Notes [Member] \| 3.00% notes due 2052 (3.00% 2052 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 1,350,000,000
Interest rate, stated percentage	3.00%
Notes [Member] \| 1.90% notes due 2025 (1.90% 2025 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 500,000,000
Interest rate, stated percentage	1.90%	1.90%
Notes [Member] \| 2.20% notes due 2027 (2.20% 2027 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 1,750,000,000
Interest rate, stated percentage	2.20%	2.20%
Notes [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 1,250,000,000
Interest rate, stated percentage	2.45%	2.45%
Notes [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 1,250,000,000
Interest rate, stated percentage	2.30%	2.30%
Notes [Member] \| 3.15% notes due 2040 (3.15% 2040 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 2,000,000,000
Interest rate, stated percentage	3.15%	3.15%
Notes [Member] \| 3.375% notes due 2050 (3.375% 2050 Notes)
Debt Instrument [Line Items]
Aggregate principal amount of notes issued		$ 2,250,000,000
Interest rate, stated percentage	3.375%	3.375%

Financing arrangements (Debt Re

Financing arrangements (Debt Repayments) (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)
Debt Instrument [Line Items]
Repayments of debt	$ 4,150		$ 6,450	$ 4,514
Make-whole payments recognized in interest expense	1,197		1,262	1,289
Notes [Member]
Debt Instrument [Line Items]
Repayments of debt	4,200		6,500	4,500
Make-whole payments recognized in interest expense	$ 24		$ 96
Notes [Member] \| 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt				$ 1,400
Interest rate, stated percentage				2.20%	2.20%
Notes [Member] \| 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt				$ 1,000
Interest rate, stated percentage				5.70%	5.70%
Notes [Member] \| 2.125% 2019 Euro Notes
Debt Instrument [Line Items]
Repayments of debt \| €					€ 675
Interest rate, stated percentage			2.125%	2.125%	2.125%
Notes [Member] \| 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt				$ 700
Interest rate, stated percentage				1.90%	1.90%
Notes [Member] \| Floating Rate Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of debt				$ 550
Notes [Member] \| 4.50% notes due 2020 (4.50% 2020 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 300
Interest rate, stated percentage			4.50%
Notes [Member] \| 2.125% notes due 2020 (2.125% 2020 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 750	$ 864
Interest rate, stated percentage			2.125%
Notes [Member] \| 2.20% notes due 2020 (2.20% 2020 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 700
Interest rate, stated percentage			2.20%
Notes [Member] \| 3.45% notes due 2020 (3.45% 2020 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 900
Interest rate, stated percentage			3.45%
Notes [Member] \| Floating Rate Notes Due 2020
Debt Instrument [Line Items]
Repayments of debt			$ 300
Notes [Member] \| 4.10% notes due 2021 (4.10% 2021 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 1,000
Interest rate, stated percentage			4.10%
Notes [Member] \| 1.85% notes due 2021 (1.85% 2021 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 750
Interest rate, stated percentage			1.85%
Notes [Member] \| 3.875% notes due 2021 (3.875% 2021 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 1,750
Interest rate, stated percentage			3.875%
Notes [Member] \| 1.25% notes due 2022 (1.25% 2022 Notes)
Debt Instrument [Line Items]
Repayments of debt \| €		€ 1,250
Interest rate, stated percentage	1.25%	1.25%
Notes [Member] \| 2.70% notes due 2022 (2.70% 2022 Notes)
Debt Instrument [Line Items]
Repayments of debt	$ 500
Interest rate, stated percentage	2.70%	2.70%
Notes [Member] \| 2.65% notes due 2022 (2.65% 2022 Notes)
Debt Instrument [Line Items]
Repayments of debt			$ 1,500
Interest rate, stated percentage	2.65%	2.65%
Notes [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes)
Debt Instrument [Line Items]
Repayments of debt	$ 750
Interest rate, stated percentage	3.625%	3.625%	3.625%
Notes [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%	2.45%
Notes [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%	2.30%	2.30%

Financing arrangements (Interes

Financing arrangements (Interest Rate and Cross-currency Swaps) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2021CHF (SFr)	Dec. 31, 2021GBP (£)
Debt Instrument [Line Items]
Net Cash Provided by (Used in) Operating Activities	$ 9,261	$ 10,497	$ 9,150
Repayments of debt	4,150	6,450	4,514
Interest rate swap contracts [Member] \| Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Notional amount	6,700	5,900
Derivative, Notional Amount, Amount Terminated	$ 750	3,650
Net Cash Provided by (Used in) Operating Activities		576
Interest Rate Swap, One [Member] \| Interest rate swap contracts [Member] \| Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Derivative, Notional Amount, Amount Terminated		5,200
Interest Rate Swap, Two [Member] \| Interest rate swap contracts [Member] \| Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Notional amount		5,200
0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%			0.41%	0.41%	0.41%
0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds) \| Cross-currency swap contract [Member] \| Cash flow hedge [Member]
Debt Instrument [Line Items]
Notional amount	$ 704				SFr 700,000,000
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) \| Cross-currency swap contract [Member] \| Cash flow hedge [Member]
Debt Instrument [Line Items]
Notional amount	833			€ 750,000,000
5.50% 2026 pound sterling Notes [Member] \| Cross-currency swap contract [Member] \| Cash flow hedge [Member]
Debt Instrument [Line Items]
Notional amount	747					£ 475,000,000
4.00% 2029 pound sterling Notes [Member] \| Cross-currency swap contract [Member] \| Cash flow hedge [Member]
Debt Instrument [Line Items]
Notional amount	$ 1,111					£ 700,000,000
1.25% 2022 euro Notes [Member] \| Cross-currency swap contract [Member] \| Cash flow hedge [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%			1.25%	1.25%	1.25%
Notional amount \| €				€ 1,250,000,000
Notes payable [Member]
Debt Instrument [Line Items]
Notional amount	$ 6,650	5,900
Notes payable [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%			3.625%	3.625%	3.625%
Notional amount	$ 0	$ 750
Notes payable [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate		2.70%
Notes payable [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%			0.41%	0.41%	0.41%
Notes payable [Member] \| 3.625% notes due 2024 (3.625% 2024 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%			3.625%	3.625%	3.625%
Notional amount	$ 1,400	$ 1,400
Notes payable [Member] \| 3.625% notes due 2024 (3.625% 2024 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	3.20%	3.20%		3.20%	3.20%	3.20%
Notes payable [Member] \| 3.125% notes due 2025 (3.125% 2025 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%			3.125%	3.125%	3.125%
Notional amount	$ 1,000	$ 1,000
Notes payable [Member] \| 3.125% notes due 2025 (3.125% 2025 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.80%	1.80%		1.80%	1.80%	1.80%
Notes payable [Member] \| 2.600% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%			2.60%	2.60%	2.60%
Notional amount	$ 1,250	$ 1,250
Notes payable [Member] \| 2.600% notes due 2026 (2.60% 2026 notes) [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.80%	1.80%		1.80%	1.80%	1.80%
Notes payable [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%			2.00%	2.00%	2.00%
Notes payable [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%			2.45%	2.45%	2.45%
Notional amount	$ 1,000	$ 0
Notes payable [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.00%			1.00%	1.00%	1.00%
Notes payable [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%			2.30%	2.30%	2.30%
Notional amount	$ 500	0
Notes payable [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	0.80%			0.80%	0.80%	0.80%
Notes payable [Member] \| 4.663% notes due 2051 (4.663% 2051 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%			4.663%	4.663%	4.663%
Notional amount	$ 1,500	1,500
Notes payable [Member] \| 4.663% notes due 2051 (4.663% 2051 Notes) \| LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	4.10%			4.10%	4.10%	4.10%
Notes [Member]
Debt Instrument [Line Items]
Face amount	$ 5,000	9,000
Repayments of debt	$ 4,200	$ 6,500	$ 4,500
Notes [Member] \| 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage			2.20%
Repayments of debt			$ 1,400
Notes [Member] \| 3.45% notes due 2020 (3.45% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage		3.45%
Repayments of debt		$ 900
Notes [Member] \| 4.10% notes due 2021 (4.10% 2021 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage		4.10%
Repayments of debt		$ 1,000
Notes [Member] \| 3.875% notes due 2021 (3.875% 2021 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage		3.875%
Repayments of debt		$ 1,750
Notes [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%		3.625%	3.625%	3.625%
Repayments of debt	$ 750
Notes [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%			0.41%	0.41%	0.41%
Face amount \| SFr					SFr 700,000,000
Notes [Member] \| 3.625% notes due 2024 (3.625% 2024 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%		3.625%	3.625%	3.625%
Notes [Member] \| 3.125% notes due 2025 (3.125% 2025 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%		3.125%	3.125%	3.125%
Notes [Member] \| 2.600% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%		2.60%	2.60%	2.60%
Notes [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%			2.00%	2.00%	2.00%
Face amount \| €				€ 750,000,000
Notes [Member] \| 5.50% 2026 pound sterling Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%			5.50%	5.50%	5.50%
Face amount \| £						£ 475,000,000
Notes [Member] \| 6.375% notes due 2037 (6.375% 2037 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%	6.375%		6.375%	6.375%	6.375%
Debt Conversion, Converted Instrument, Amount		$ 74
Notes [Member] \| 4.00% 2029 pound sterling Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.00%			4.00%	4.00%	4.00%
Face amount \| £						£ 700,000,000
Notes [Member] \| 2.45% notes due 2030 (2.45% 2030 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%		2.45%	2.45%	2.45%
Notional amount	$ 1,000
Face amount		$ 1,250
Notes [Member] \| 2.30% notes due 2031 (2.30% 2031 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%	2.30%		2.30%	2.30%	2.30%
Notional amount	$ 500
Face amount		$ 1,250
Notes [Member] \| 6.90% notes due 2038 (6.90% 2038 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%	6.90%		6.90%	6.90%	6.90%
Debt Conversion, Converted Instrument, Amount		$ 37
Notes [Member] \| 6.40% notes due 2039 (6.40% 2039 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%	6.40%		6.40%	6.40%	6.40%
Debt Conversion, Converted Instrument, Amount		$ 133
Notes [Member] \| 5.75% notes due 2040 (5.75% 2040 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%		5.75%	5.75%	5.75%
Debt Conversion, Converted Instrument, Amount		$ 39
Notes [Member] \| 5.15% notes due 2041 (5.15% 2041 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%		5.15%	5.15%	5.15%
Debt Conversion, Converted Instrument, Amount		$ 245
Notes [Member] \| 5.65% notes due 2042 (5.65% 2042 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%		5.65%	5.65%	5.65%
Debt Conversion, Converted Instrument, Amount		$ 72
Notes [Member] \| 5.375% notes due 2043 (5.375% 2043 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%	5.375%		5.375%	5.375%	5.375%
Debt Conversion, Converted Instrument, Amount		$ 76
Notes [Member] \| 4.663% notes due 2051 (4.663% 2051 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%		4.663%	4.663%	4.663%
Notes [Member] \| 2.77% notes due 2053 (2.77% 2053 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.77%	2.77%		2.77%	2.77%	2.77%
Face amount		$ 940
Debt exchange additional cash consideration		85
Debt Instrument, Unamortized Discount		$ 264
Notes [Member] \| 1.25% 2022 euro Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%	1.25%		1.25%	1.25%	1.25%
Repayments of debt			1,400
Notes [Member] \| 2.125% notes due 2020 (2.125% 2020 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage		2.125%
Repayments of debt		$ 750	$ 864

Financing arrangements (Shelf R

Financing arrangements (Shelf Registration Statements and Other Facilities) (Details) - Line of credit [Member]	12 Months Ended
	Dec. 31, 2021USD ($)renewal_option	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement	$ 2,500,000,000
Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks	$ 750,000,000
Initial commitment term of each bank which is a party to the agreement	5 years
Number of additional term extension options \| renewal_option	2
Additional period for extension of commitment term	1 year
Annual commitment fees for syndicated, unsecured, revolving credit agreement	0.09%
Amount outstanding under syndicated, unsecured, revolving credit facility	$ 0	$ 0
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Description of variable rate basis	one-month LIBOR

Financing arrangements (Contrac

Financing arrangements (Contractual Maturities of Long-term Debt) (Details) $ in Millions	Dec. 31, 2021USD ($)
Maturities of Long-term Debt [Abstract]
2022	$ 0
2023	1,517
2024	1,400
2025	1,500
2026	2,746
Thereafter	27,075
Total	$ 34,238

Financing arrangements (Inter_2

Financing arrangements (Interest Costs) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Interest paid, net of interest rate and cross currency swaps	$ 1.2	$ 1.2	$ 1.3

Stockholders' equity (Stock Rep

Stockholders' equity (Stock Repurchase Program) (Details) - USD ($) shares in Millions	3 Months Ended												12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2021
Equity [Abstract]
Stock repurchases, Shares	6.9	4.6	6.5	3.7	5.3	3	2.6	4.3	5.1	6.2	13.1	15.9	21.7	15.2	40.2
Stock repurchases	$ 1,461,000,000	$ 1,069,000,000	$ 1,592,000,000	$ 865,000,000	$ 1,221,000,000	$ 752,000,000	$ 591,000,000	$ 933,000,000	$ 1,090,000,000	$ 1,170,000,000	$ 2,349,000,000	$ 3,031,000,000	$ 4,987,000,000	$ 3,497,000,000	$ 7,640,000,000
Stock repurchase program, additional authorized amount	5,000,000,000			$ 3,400,000,000									5,000,000,000			$ 4,500,000,000
Amount available for stock repurchases under a board approved stock repurchase plan	$ 10,900,000,000												$ 10,900,000,000

Stockholders' equity (Dividends

Stockholders' equity (Dividends) (Details) - $ / shares	Mar. 08, 2022	Dec. 03, 2021	Oct. 31, 2021	Jul. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Jul. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Oct. 31, 2019	Jul. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Common stock, dividends declared per share (in usd per share)		$ 1.94	$ 1.76	$ 1.76	$ 1.76	$ 1.76	$ 1.60	$ 1.60	$ 1.60	$ 1.60	$ 1.45	$ 1.45	$ 1.45	$ 1.45													$ 7.22	$ 6.56	$ 5.95
Common stock, dividends paid per share (in usd per share)															$ 1.76	$ 1.76	$ 1.76	$ 1.76	$ 1.60	$ 1.60	$ 1.60	$ 1.60	$ 1.45	$ 1.45	$ 1.45	$ 1.45
Forecast
Class of Stock [Line Items]
Common stock, dividends paid per share (in usd per share)	$ 1.94

Stockholders' equity (Component

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 9,409	$ 9,673	$ 12,500
Foreign currency translation adjustments	(135)	9	(48)
Ending Balance	6,700	9,409	9,673
Cumulative effect of changes in accounting principles, net of taxes
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance		(2)
Ending Balance			(2)
Foreign currency translation [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(709)	(718)	(670)
Foreign currency translation adjustments	(135)	9	(48)
Income taxes	0	0	0
Ending Balance	(844)	(709)	(718)
Cash flow hedges [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(263)	175	241
Unrealized gains (losses)	159	(61)	127
Reclassification adjustments to income	(253)	501	(211)
Income taxes	(88)	124	18
Ending Balance	61	(263)	175
Available-for-sale securities [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	1	22	(338)
Unrealized gains (losses)	(1)	6	424
Reclassification adjustments to income	0	33	(56)
Income taxes	0	6	(8)
Ending Balance	0	1	22
Other [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(14)	(7)	(2)
Other gains	1	(7)	(5)
Ending Balance	(13)	(14)	(7)
AOCI [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(985)	(528)	(769)
Foreign currency translation adjustments	(135)	9	(48)
Unrealized gains (losses)	158	(55)	551
Reclassification adjustments to income	253	(534)	(267)
Other gains	1	(7)	(5)
Income taxes	(88)	130	10
Ending Balance	$ (796)	$ (985)	$ (528)

Stockholders' equity (Accumulat

Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities		$ 7	$ 14
Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities		(1)	(22)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	$ 33	(14)	28
Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges	$ 55	$ (110)	$ (46)

Stockholders' equity (Reclassif

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues	$ 25,979	$ 25,424	$ 23,362
Other income, net	259	256	753
Interest expense, net	(1,197)	(1,262)	(1,289)
Income before income taxes	6,701	8,133	9,138
Provision for income taxes	(808)	(869)	(1,296)
Net income	5,893	7,264	7,842
Product sales
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues	24,297	24,240	22,204
Reclassification out of AOCI [Member] \| Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(253)	501	211
Provision for income taxes	55	(110)	(46)
Net income	(198)	391	165
Reclassification out of AOCI [Member] \| Available-for-sale securities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	0	33	56
Provision for income taxes	0	(7)	(14)
Net income	0	26	42
Reclassification out of AOCI [Member] \| Foreign currency contract [Member] \| Product sales \| Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues	(8)	178	101
Reclassification out of AOCI [Member] \| Cross-currency swap contract [Member] \| Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	$ (245)	$ 323	$ 110

Stockholders' equity (Other) (D

Stockholders' equity (Other) (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Preferred stock shares authorized (in shares)	5,000,000
Preferred stock, par value (in usd per share)	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Fair value measurement - (Fair

Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Assets:
Interest-bearing securities	$ 7,304	$ 9,845
Equity securities	831	477
Derivatives:
Total assets	8,400	10,671
Derivatives:
Contingent consideration obligations	342	33	$ 61	$ 72
Total liabilities	876	603
Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	183	28
Derivatives:
Foreign currency and cross-currency swap contracts	39	237
Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	66	255
Derivatives:
Foreign currency and cross-currency swap contracts	339	318
Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	16	66
Derivatives:
Interest rate swap contracts	156	15
U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	47	130
U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	1,400	4,948
Money market mutual funds [Member]
Assets:
Interest-bearing securities	5,856	4,765
Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	1	2
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	611	477
Derivatives:
Total assets	7,914	10,320
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	47	130
Quoted prices in active markets for identical assets (Level 1) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	1,400	4,948
Quoted prices in active markets for identical assets (Level 1) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	5,856	4,765
Quoted prices in active markets for identical assets (Level 1) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	266	351
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	534	570
Significant other observable inputs (Level 2) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	183	28
Derivatives:
Foreign currency and cross-currency swap contracts	39	237
Significant other observable inputs (Level 2) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	66	255
Derivatives:
Foreign currency and cross-currency swap contracts	339	318
Significant other observable inputs (Level 2) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	16	66
Derivatives:
Interest rate swap contracts	156	15
Significant other observable inputs (Level 2) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	1	2
Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	220	0
Derivatives:
Total assets	220	0
Derivatives:
Contingent consideration obligations	342	33
Total liabilities	342	33
Significant unobservable inputs (Level 3) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	$ 0	$ 0

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 02, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Length of time hedged in foreign currency contracts	3 years
Aggregate fair value of long-term debt, including current portion	$ 37,900	$ 39,400
Carrying value of long-term debt, including current portion	33,309	32,986
Contingent consideration obligations	342	33		$ 61	$ 72
BeiGene
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Method Investment, Quoted Market Value	5,100	4,900	$ 2,600
Approximate carrying value of the company's equity method investment	$ 2,800	$ 2,900

Fair value measurement - Contin

Fair value measurement - Contingent Consideration Obligations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Beginning balance	$ 33	$ 61	$ 72
Additions	309	0	0
Payments	(7)	(6)	0
Net changes in valuations	7	(22)	(11)
Ending balance	342	$ 33	$ 61
Teneobio, Inc.
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 1,600

Derivative instruments - Narrat

Derivative instruments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Derivative Instrument, Term	3 years
Net Cash Provided by (Used in) Operating Activities	$ 9,261	$ 10,497	$ 9,150
Long-term debt
Derivative Instruments Gain Loss [Line Items]
Carrying amounts of hedged liabilities	6,729	6,258
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps	19
Interest rate swap [Member] \| Interest Expense [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, Gain on Derivative		40
Interest Rate Swap, At-Then Current Interest Rates [Member] \| Long-term debt
Derivative Instruments Gain Loss [Line Items]
Carrying amounts of hedged liabilities		5,200
Derivatives designated as hedging instruments [Member] \| Foreign currency forward contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	5,700	5,100	5,000
Derivatives designated as hedging instruments [Member] \| Interest rate swap [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	6,700	5,900
Derivative, Notional Amount, Amount Terminated	750	3,650
Net Cash Provided by (Used in) Operating Activities		576
Derivative Instrument, Aggregate Notional Amount of New Instruments	1,500
Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities	750	5,200
Derivatives designated as hedging instruments [Member] \| Interest rate swap [Member] \| Interest Rate Swap, Two [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount		5,200
Derivatives not designated as hedging instruments [Member] \| Foreign currency forward contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	$ 680	$ 1,000	$ 1,200
Notes [Member] \| 2.125% 2019 Euro Notes
Derivative Instruments Gain Loss [Line Items]
Interest rate, stated percentage		2.125%	2.125%

Derivative instruments - (Cross

Derivative instruments - (Cross-currency Swaps) (Details) € in Millions, £ in Millions, SFr in Millions, $ in Millions	Dec. 31, 2021EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2021CHF (SFr)	Dec. 31, 2021GBP (£)	Dec. 31, 2020	Dec. 31, 2019
2.125% 2019 Euro Notes \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage					2.125%	2.125%
1.25% 2022 euro Notes [Member] \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%	1.25%
0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Derivative [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds) \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
5.50% 2026 pound sterling Notes [Member] \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
4.00% 2029 pound sterling Notes [Member] \| Notes [Member]
Derivative [Line Items]
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amount	€ 1,250
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Derivative [Line Items]
Notional amount		$ 704	SFr 700
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Derivative [Line Items]
Notional amount	€ 750	833
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amount		747		£ 475
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amount		$ 1,111		£ 700
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| Euro Member Countries, Euro [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| Switzerland, Francs [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Derivative [Line Items]
Interest rates	0.40%	0.40%	0.40%	0.40%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United Kingdom, Pounds [Member] \| 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United Kingdom, Pounds [Member] \| 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United States of America, Dollars [Member] \| 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United States of America, Dollars [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United States of America, Dollars [Member] \| 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
Cash flow hedge [Member] \| Cross-currency swap contracts [Member] \| United States of America, Dollars [Member] \| 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments - (Effec

Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains (losses)	$ 159	$ (61)	$ 127
Foreign currency contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains (losses)	373	(251)	148
Cross-currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains (losses)	$ (214)	$ 190	$ (21)

Derivative instruments - (Hedge

Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ 284	$ 566
Current portion of long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	85	89
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	85	89
Carrying value with discontinued hedging relationships	85	89
Hedging adjustments on discontinued hedging relationships	85	89
Long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	6,729	6,258
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	199	477
Carrying value with discontinued hedging relationships	440	525
Hedging adjustments on discontinued hedging relationships	$ 340	$ 425

Derivative instruments - (Summa

Derivative instruments - (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 25,979	$ 25,424	$ 23,362
Other income, net	259	256	753
Interest expense, net	(1,197)	(1,262)	(1,289)
Interest rate swap agreements [Member]
Derivative [Line Items]
Gains (losses) on fair value hedging relationships, Hedged Items	281	315	(349)
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments	(192)	(204)	352
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Cross-currency swap contracts [Member]
Derivative [Line Items]
Other income, net	(245)	323	110
Product sales
Derivative [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	24,297	24,240	22,204
Product sales \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Foreign currency contracts [Member]
Derivative [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ (8)	$ 178	$ 101

Derivative instruments - (Fair

Derivative instruments - (Fair Value of Derivatives) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Total derivative assets, fair value	$ 265	$ 349
Liabilities
Total derivative liabilities, fair value	534	570
Derivatives designated as hedging instruments [Member]
Assets
Total derivative assets, fair value	265	349
Liabilities
Total derivative liabilities, fair value	534	570
Derivatives designated as hedging instruments [Member] \| Foreign currency contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	183	28
Derivatives designated as hedging instruments [Member] \| Foreign currency contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	39	237
Derivatives designated as hedging instruments [Member] \| Cross-currency swap contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	66	255
Derivatives designated as hedging instruments [Member] \| Cross-currency swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	339	318
Derivatives designated as hedging instruments [Member] \| Interest rate swap contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	16	66
Derivatives designated as hedging instruments [Member] \| Interest rate swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 156	$ 15

Contingencies and commitments (

Contingencies and commitments (Sandoz Patent Litigation) (Details)	1 Months Ended
	Jun. 30, 2018lawsuit
Sandoz Inc.
Gain Contingencies [Line Items]
Number of lawsuits filed	19

Contingencies and commitments_2

Contingencies and commitments (Immunex and Sandoz Litigation) (Details)	1 Months Ended
	Apr. 30, 2019affiliate
Immunex/Samsung Bioepis Co.
Other Commitments [Line Items]
Gain contingency, number of affiliates	2

Contingencies and commitments_3

Contingencies and commitments (Repatha Patent Litigation) (Details) - Sanofi/Regeneron Patent Litigation - patent	1 Months Ended
	Mar. 31, 2018	Feb. 28, 2016	Oct. 31, 2014
Other Commitments [Line Items]
Number of patents allegedly infringed			7
Length of trial		5 days
Number of challenges	2

Contingencies and commitments_4

Contingencies and commitments (Additional Information) (Details) $ in Millions	Jun. 02, 2021USD ($)claim	Jul. 31, 2019lawsuit	Apr. 30, 2019claim	Apr. 30, 2019agreement	May 31, 2019complaints	Apr. 30, 2019plaintiffslawsuitclaim	Oct. 26, 2021claim	May 31, 2020claim	Jun. 04, 2019claim	May 20, 2019claim
Loss Contingencies [Line Items]
Number of claims										1
Novartis Breach Of Contract Action
Loss Contingencies [Line Items]
Number of claims	2						2
Loss Contingency, Damages Paid, Value \| $	$ 48
Agreements breached \| agreement				2
Sensipar Antitrust Class Actions
Loss Contingencies [Line Items]
Loss contingency, number of plaintiffs \| plaintiffs						4
Loss contingency, number of lawsuits			4			2
Loss contingency, number of lawsuits filed \| lawsuit		4				4
Humira Biosimilar Antitrust Class Actions
Loss Contingencies [Line Items]
Number of claims								12	12
Number of complaints stayed \| complaints					6

Contingencies and commitments_5

Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details) $ in Millions	Dec. 31, 2021USD ($)installment
Commitments and Contingencies Disclosure [Abstract]
U.S. repatriation tax commitments, number of annual installments \| installment	8
U.S. repatriation tax commitments, 2022	$ 587
U.S. repatriation tax commitments, 2023	1,100
U.S. repatriation tax commitments, 2024	1,467
U.S. repatriation tax commitments, 2025	1,834
Total remaining U.S. repatriation tax commitments	$ 4,988

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts [Roll Forward]
Balance at beginning of period	$ 32	$ 26	$ 48
Additions charged to costs and expenses	0	8	0
Other additions	0	0	0
Deductions	(6)	(2)	(22)
Balance at end of period	$ 26	$ 32	$ 26